SlideShare a Scribd company logo
Society of Investment Professionals in Germany
	
Digital Transformation in Healthcare
13 June 2017
DVFA Center, Frankfurt am Main
	10th DVFA Life Science Conference
Supported by
Media Partner
Schnee Research
Plattform
Life Sciences
Networking Partner
Conference Proceedings
LIFE SCIENCE_
Disclaimer_
This brochure contains information from sources believed to be reliable but has not been
verified or testified. The corporate data provided has been transmitted and converted elec-
tronically. Therefore, the information cannot be guaranteed to be secure or error-free as the
transmitted and converted information could be intercepted, corrupted, lost or incomplete.
Thus, DVFA does not accept liability for any errors or omissions regarding the contents of
this information. Financial data presented by the companies as reported by the corporates.
The conference brochure is provided for information purposes and should not be construed
as a solicitation or offer to buy or sell any securities or related financial instruments.
Please note that the data given in this brochure may be rounded. Deviations may thus oc-
cur, e.g. regarding percentage figures.
The company information is provided by the respective companies. DVFA cannot assume
any responsibility for the correctness and completeness of this information.
Any copying, distribution or any action taken or omitted to be taken in reliance on it is pro-
hibited and may be unlawful.
© 2017 DVFA GmbH
ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval
system, or transmitted, in any form or by any means, electronic, mechanical, photocopying,
recording, or otherwise, without the prior written permission of the publisher and the co-
pyright holder.
The 10th DVFA Life Science Conference focused on the challenges and opportunities of Digital Transformation in Healthcare. With
the explosive growth in health and biomedical data the digital transformation of the healthcare sector is gaining momentum.
Participants got insights in Network medicine, Telematics Infrastructure, Electronic Health Records (EHR), Medical Apps &
Cloud, EU data protection rules and discuss the future of digital medicine with industry experts.
u	Topics
	Digital Transformation in Healthcare: Challenges & Opportunities
	 The Telematics Infrastructure: The coming eHealth Revolution in Germany
	 Connected Diabetes Management
	 Increased data protection and data security requirements under the new EU Data Protection Regulation
	 Panel Discussion – New Business Models Digital Health
	 Next Generation Sequencing & Big Data
	 The Health Revolution – Better Outcomes with Smart Data
	 Panel Discussion – Digital Health: A Capital Market Perspective
	 Digital Health – Startup-Slam
u	Speakers & Moderators
	Dr. Christa Bähr, CEFA, CFA, Founder and Business Owner, CB HealthCare	
	Kai Brüning, CEFA, Fundsmanager, apoAsset Management GmbH	
	Eric Cohen, IR, Cellnovo Group
	Dr. Lothar Ende, Partner, HEUKING KÜHN LÜER WOJTEK
	Jason Gammack, Vice President Head of Marketing Life Sciences, QIAGEN N.V.
	Dr. Lutz Martin Keppeler, Senior Associate, Certified Specialist Lawyer for Information Technology Law,			
HEUKING KÜHN LÜER WOJTEK	
	Prof. Dr. Dr. Gerhard Lingg PhD, Chairman, imi mHealth Solutions Ltd.
	Dr. med. Markus Manns, Chairman DVFA Life Science Commission, Equities Fund Manager, Union Investment		
Privatfonds GmbH	
	Klaus May, Geschäftsführer, Genomatix
	Dr. Martin Pöhlchen, Partner, Alira Health
	Karlheinz Schmelig, Managing Partner, Creathor Venture
	Carsten Schmitt, Investment Banking, Renell Bank	
	Dr. Julia Schüler, CBA, Investor Relations, SynapCon
	Roman Schweiger, CFO, HUMANOO
	Julian Shapley, CSO, Cellnovo Group
	Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE
	Dr. Klaus Suwelack, New Venture Lead Germany, Johnson & Johnson Innovation/Janssen
	Christian B. Teig, CFO, CompuGroup Medical
	Lesli Wagstaffe, CEO, imi mHealth Solutions Ltd.				
LIFE SCIENCE_
Conference 13 June 2017, 9 a.m.
LIFE SCIENCE
DVFA LIFE SCIENCE CONFERENCE_
08:45 a.m	.	u	Check-in
09:00 a.m.	u	Welcome			
Dr. Christa Bähr, CEFA, CFA, Chairwoman DVFA Life Science Commission, 			
CB HealthCare				
09:10 a.m. u	Digital Transformation in Healthcare – Challenges & Opportunities
Dr. Martin Pöhlchen, Partner, Alira Health - Presentation
09:45 a.m. 	u	The Telematics Infrastructure: The Coming eHealth Revolution in Germany			
Christian B. Teig, CFO, CompuGroup Medical - Presentation	
10:20 a.m. u	Connected Diabetes Management - Presentation			
Julian Shapley, CSO, and Eric Cohen, IR, Cellnovo Group
10:50 a.m. 	u	Coffee Break
11:10 a.m. 	u	Increased Data Protection and Data Security Requirements under the 			
New EU Data Protection Regulation - Presentation
Dr. Lothar Ende, Partner, and Dr. Lutz Martin Keppeler, Senior Associate,
Certified Specialist Lawyer for Information Technology Law, HEUKING
KÜHN LÜER WOJTEK
11:45 a.m. 	u	Panel I: New Business Modells Digital Health
•	 Dr. Lutz Martin Keppeler, Senior Associate, Certified Specialist Lawyer for
Information Technology Law, HEUKING KÜHN LÜER WOJTEK
•	 Dr. Martin Pöhlchen, Partner, Alira Health
•	 Karlheinz Schmelig, Managing Partner, Creathor Venture - Presentation
•	 Christian B. Teig, CFO, CompuGroup Medical
•	 Moderation: Dr. Klaus Suwelack, New Venture Lead Germany, Johnson &
Johnson Innovation/Janssen
12:45 p.m. 	u	Lunch	
01:30 p.m. u	Next Generation Sequencing & Big Data - Presentation			
Jason Gammack, Vice President Head of Marketing Life Sciences, QIAGEN N.V.	
02:05 p.m. u	The Health Revolution – Better Outcomes with Smart Data - Presentation			
Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE
02:40 p.m. 	u	Coffee Break
03:00 p.m. 	u	Panel II: Digital Health - A Capital Market Perspective
•	 Kai Brüning, CEFA, Fundsmanager, apoAsset Management GmbH
•	 Prof. Dr. Dr. Gerhard Lingg PhD, Chairman, imi mHealth Solutions Ltd.
•	 Carsten Schmitt, Investment Banking, Renell Bank
•	 Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE
•	 Moderation: Dr. med. Markus Manns, Chairman DVFA Life Science
Commission, Equities Fund Manager, Union Investment Privatfonds
GmbH
04:00 p.m. 	u	Digital Health - Startup-Slam
•	 Genomatix: Klaus May, Geschäftsführer - Presentation not released
•	 HUMANOO: Roman Schweiger, CFO - Presentation
•	 imi mHealth Solutions Ltd.: Lesli Wagstaffe, CEO
•	 SynapCon: Dr. Julia Schüler, CBA, Investor Relations - Presentation
not released
•	 Moderation: Karlheinz Schmelig, Managing Partner, Creathor Venture
04:45 p.m. 	u	Get-together
Programme
				
13 June 2017
Clicking on the title will take
you directly to the appropriate
page.
June 13, 2017
Digital Transformation in Healthcare –
Challenges & Opportunities
Dr. Martin Pöhlchen
Partner, Germany
2
Strictly Confidential
Strategy. Execution. Innovation.
Alira Health is an
international
advisory firm
providing integrated
strategy, execution
and innovation
services for
healthcare and life
science companies.
STRATEGY EXECUTION INNOVATION
CORPORATE STRATEGY
MARKET ACCESS
MARKET RESEARCH
COMMERCIAL DUE DILIGENCE
IP AND PRODUCT PORTFOLIO
STRATEGY
REIMBURSEMENT AND PRICING
HEALTH ECONOMICS
REGULATORY STRATEGY
LEADERSHIP EMPOWERMENT
VALUATION AND FAIRNESS OPINION
SELL AND BUY ADVISORY
STRATEGIC PARTNERSHIP
AND ALLIANCE MANAGEMENT
GROWTH CAPITAL
AND EXPANSION FINANCING
IN- AND OUT-LICENSING
SCIENTIFIC AND CLINICAL
DUE DILIGENCE
BUSINESS DEVELOPMENT
PROJECT MANAGEMENT
FOR REGULATORY SUBMISSION
PRECLINICAL AND CLINICAL TRIALS
CLINICAL COMMUNICATION AND
EDUCATION
NEW PRODUCT DEVELOPMENT
NEW IP DEVELOPMENT
CLINICAL AND SCIENTIFIC GUIDANCE
ON INNOVATION
INCUBATION OF
BREAKTHROUGH TECHNOLOGIES
3
Strictly Confidential
Our Knowledge. Your Power.
Patient
» Biotech and R&D Companies
» RX Pharmaceuticals » Orphan Pharmaceuticals
» Specialty Pharmaceuticals » Primary Care Therapies
» Generics » Active Pharmaceutical Ingredients
» Contract Manufacturing Organization
» Contract Research Organization
» Over the Counter » Consumer Care
» Nutraceuticals
» Cosmetics
» Critical Care
» Wound Care
» Medical Imaging
» Infection Control
» Drug Delivery
» Fluid Management
» Cardiovascular
» Neurovascular
» Interventional Devices
» Surgical Equipment
» Orthopedics
» In Vitro Diagnostics
» Laboratory» Health Education
» Health Data Analytics
» Population Health Management
» Telehealth
» Electronic Medical Records
» Big Data
» Pharmacy Management Systems
» Revenue Cycle Management
» Precision Medicine
» Wearables
» Patient Monitoring
» Telemedicine
» Biostatistics
» Drug Adherence
» Drug & Device
Combination
Products
» Companion
Diagnostics
Payers
Healthcare
Providers
Product
& Solution
Suppliers
Our expertise
extends beyond
the walls of
convention and
throughout every
life science and
healthcare sector.
4
Strictly Confidential
Source: Berger, Roland (2016). Digital health market development 2015-2020 [USD bn].
39
48
59
73
89
110
8
14
21
28
37
46
12
14
17
19
22
26
20
20
21
22
23
24
-
50
100
150
200
250
2015 2016 2017 2018 2019 2020
Wireless Health Mobile Health Telehealth EMR/HER
+23%
+41%
+15%
+4%
79
96
118
142
172
206>
+21% p.a.
The Digital Health
industry is
expected to grow
at an annual rate
>20 %.
5
Strictly Confidential
Source: Berger, Roland (2016). Digital health market development 2015-2020 [USD bn].
Hypothesis: the
digital healthcare
revolution will
come from R&D.
DIGITAL VALUE POCKETS ALONG WITH THE VALUE CHAIN
Understand how digitalization will impact your market segment
R&D
MANUFACTURING/
SUPPLY CHAIN
MEDICAL/
MARKETING
SALES
Pharma
Companies
Digital
Tools
SMART DATA
INDUSTRY 4.0 DIGITAL HEALTH
MULTICHANNEL
MANAGEMENT
6
Strictly Confidential
The era of the
Frank Zappa drug
development
strategy comes to
an end. However,
the non-
responder
problem persists.
7
Strictly Confidential
From closed expert
systems to
informed
customers
Drug
Development
Monitoring
Prevention
Imaging
Electronic
Health Record
Proteomics
Metabolics
Genomics
Lab
Management
System
Mobile Health
Social Media
Quantified Self
Customer
8
Strictly Confidential
▪ Stronger engagement of IT companies in Digital Health
▪ New business models and cooperation in Digital Health
• Cooperation with new players who directly connect R&D with payers and patients
▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in
Digital Health
9
Strictly Confidential
▪ Stronger engagement of IT companies in Digital Health
▪ New business models and cooperation in Digital Health
• Cooperation with new players who directly connect R&D with payers and patients
▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in
Digital Health
10
Strictly Confidential
Stronger engagement of IT companies in Digital Health (1)
▪ Verily: “Google of human systems biology” (March 3, 2016)
• Andy Conrad, who heads up Verily (formerly known as Google Life Sciences), is working with a
coalition of academic hospitals, physiscians, universities, and patient advocates to bring medical
information into one place.
Source: Future Genomics (March 3-4, 2016). La Jolla, US. https://www.fastcompany.com/3057455/verily-is-building-a-google-for-medical-information.
11
Strictly Confidential
Stronger engagement of IT companies in Digital Health (2)
▪ Buzz: Apple plans to add 23andMe-style spit (May 8, 2015)
• Apple has designs on the DNA sequencing sector.
• The tech giant is reportedly working with research to make 23andMe-style DNA sequencing spit
kits part of ResearchKit.
• This platform turned every iPhone user into a potential study participant.
12
Strictly Confidential
Stronger engagement of IT companies in Digital Health (3)
▪ IBM launches new health unit, teams up with Apple, J&J, Medtronic (April 13, 2015)
• Launch of new company in Boston with 2,000 employees
• Analysis of 700 million iPhone users
• Acquisition of Explorys and Phytel to strengthen healthcare data analytics
13
Strictly Confidential
▪ Stronger engagement of IT companies in Digital Health
▪ New business models and cooperation in Digital Health
• Cooperation with new players who directly connect R&D with payers and patients
▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in
Digital Health
14
Strictly Confidential
Source: FierceBiotech (June 5, 2017). http://www.fiercebiotech.com/medtech/ibm-watson-novartis-join-forces-breast-cancer.
New business models and cooperation in Digital Health (1)
▪ IBM Watson, Novartis join forces on breast cancer (June 5, 2017)
• The collaboration seeks to use real-world data to better understand the expected outcomes of
various breast cancer treatments. Novartis will bring its breast cancer expertise, while IBM will
contribute its data analytics and machine learning chops.
• «As the industry shifts toward value-based care, it's critical for clinicians to understand the real-
world outcomes of therapeutics on subsets of their patients, and our goal ultimately is to put those
insights into oncologists' hands.»
15
Strictly Confidential
New business models and cooperation in Digital Health (2)
▪ Merck KGaA and Peter Thiel’s Palantir join forces to speed up R&D (January 13, 2017)
• Merck and Palantir have teamed up on big data to help the pharma industry combine its
research with other bioinformatics to zero in on those cancer patients who could be helped the
most by new meds, and then use this to help store up its R&D process.
• Palantir, which also does business with GSK, said its data analytics would be used to help Merck
«better, faster develop and deliver medicines to patients, commercialize new products and improve
patient outcomes.»
16
Strictly Confidential
New business models and cooperation in Digital Health (3)
▪ Teva taps IBM Watson for drug repurposing project (October 26, 2016)
• Three-year collaboration to build a systematic process for drug repurposing using IBM Watson
Health Cloud.
• The allies plan to develop technologies that combine machine-learning algorithms, real-world
data and human input to take some of the guesswork out of drug repurposing.
• IBM will apply Watson’s natural language processing capabilities to unstructured health data
trying to find correlations between molecules and diseases.
17
Strictly Confidential
New business models and cooperation in Digital Health (4)
▪ FDA teams with Flatiron for real-world cancer data analytics project (May 27, 2016)
• «Demonstrate the safety and efficacy of immunotherapies and other emerging anticancer drugs.
• Flatiron, an oncology analytics shop that has received funding from Google Ventures and Roche.
• Focus on the use of immunotherapies to treat advanced non-small cell lung cancer, an indication
in which Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda are approved.»
18
Strictly Confidential
New business models and cooperation in Digital Health (5)
▪ Novartis Pharmaceutical collaborates with Qualcomm in digital innovation with the Breezhaler™
inhaler device to treat COPD (January 5, 2016)
• «The collaboration further supports Novartis' focus to empower patients making it easier for them
to manage their own chronic disease by having near real time access to their own data on
inhalation use.»
19
Strictly Confidential
New business models and cooperation in Digital Health (6)
▪ AbbVie partners with Google's Calico on $1.5B R&D operation focused on aging (September 3,
2014)
• AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely
watched biotech upstart Calico on a new research operation that will cost up to $1.5B to get
started.
20
Strictly Confidential
New business models and cooperation in Digital Health (7)
▪ Data-gathering implantable chips to be tested in schizophrenia trial (November 13, 2015)
• Transformation of wearables into implantables
• Pierre Fabre tests a chip in an ongoing Phase II clinical trial of a schizophrenia drug in
development.
• The Swiss Federal Institute of Technology in Lausanne (EPFL): implantable biosensor chip to track
pH, temperature, blood glucose, while keeping tabs on the concentration of any drugs
administered to the individual.
21
Strictly Confidential
▪ Stronger engagement of IT companies in Digital Health
▪ New business models and cooperation in Digital Health
• Cooperation with new players who directly connect R&D with payers and patients
▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in
Digital Health
22
Strictly Confidential
Enormous research budgets and stronger engagement of NPOs in Digital Health (1)
▪ France plans $745M investment to build 235,000-genome-a-year sequencing operation (June 27,
2016)
• The plan is to invest approximately $745M to build a network of sequencing and analysis centers
capable of processing the equivalent of 235,000 genomes a year by 2020.
• If successful, France will make genome sequencing part of routine healthcare for people with
rare diseases and patients with metastatic, refractory cancers. The expectation is that as of 2020
France will sequence 20,000 rare disease patients and their parents.
23
Strictly Confidential
Enormous research budgets and stronger engagement of NPOs in Digital Health (2)
▪ Horizon 2020: IMI2, Big Data For Better Outcomes (December 2015)
• Provide a platform and resources for defining and developing enablers of the outcomes
transparency evolution together with patients, payers, physicians, regulators, academic
researchers, healthcare decision makers, etc. key enablers:
– Definition of outcome metrics, protocols, tools to access high quality data
– Methodologies and analytics to drive improvements
– Digital and other solutions that increase patient engagement
24
Strictly Confidential
Enormous research budgets and stronger engagement of NPOs in Digital Health (3)
▪ Medizininformatik (November 16, 2015, BMBF and extension June 2017)
• Improve patient care and research via innovative IT Systems
• These IT systems should enable usage of data from healthcare, biomedical and clinical research
without considering locations and academic institutions.
• 1st deadline: March 31, 2016, Consortia formed and approved August 2016
25
Strictly Confidential
Enormous research budgets and stronger engagement of NPOs in Digital Health (4)
▪ Health Policy: National Rural Health Mission in India
• A pilot program for 270 million school children to start a lifetime data collection, using mobile
tablets for data entry and could storage for all health data.
• Goals: determine the need for medical support, prevent epidemics, and provide analysis
capabilities to aid in the understanding of health trends across the population.
• Current figures: > 60,000 children enrolled
Source: Collaboration between Indian Ministry for Health and SAP. http://www.forbes.com/sites/sap/2014/04/10/health-in-rural-india-will-never-be-the-same.
26
Strictly Confidential
Enormous research budgets and stronger engagement of NPOs in Digital Health (5)
▪ ASCO: Health Information Technology Platform: CancerLinQ
• «Big data is about to get bigger. CancerLinQ is assembling vast amouts of usable, searchable, real-
world cancer information into a powerful database. This national initiative was inspired and
informed by the cancer experts at ASCO, so it’s not merely an exercise in IT.»
Source: ASCO & SAP (May 30, 2015) http://cancerlinq.org/.
27
Strictly Confidential
Challenges (1)
Source: Harvard Medical School, Partners Healthcare.
Data analysis not
in line with lab
analysis
Current manual methods
Automated and scalable
interpretation
Classification of gene
variants takes 20
minutes to 3 hours
0
1
10
100
1000
10000
100000
1000000
Variant Gene Panel Exome Genome
Necessaryworkinghoursfor
interpretationoftests
Type of testHorizon
28
Strictly Confidential
Challenges (2)
29
Strictly Confidential
Challenges (3)
▪ Insufficient and already outdated e-Health legislation in Germany
▪ Missing Transparency Directive for health insurance data and usage for R&D similar to Clinical
Trials Directive and other EU transparency guidelines
▪ Missing international, national and even regional harmonization concerning data security and
public acceptance
▪ Convergence of legal regulations for „Medical Records“ in the areas of „e- and Mobile Health“ as
well as new regulations for data exchange regarding „Medical Records“ in hospitals, etc. (for
example for research purposes / Biotech R&D)
30
Strictly Confidential
Challenges (4)
▪ Monolithic data silos and information gaps between biotech, pharma, CROs, patients and
healthcare providers and payers
▪ Rising costs of interpretation of data versus wet lab costs and missing reimbursement
▪ Missing technical standards for efficient exchange of data among different industries
▪ Reglatory issues (see FDA) in terms of data veracity and data security
▪ Technical challenges of semantic Web 3.0
31
Strictly Confidential
Challenges (5)
▪ Not enough well educated data scientists and executives to manage and implement Big Data
analytics at the intersections of IT, healthcare and life science
▪ Public perception and unpredictable user behavior concerning Quantified Self Movement and
data security
▪ Industry transformation in healthcare and life science from expert systems to customer oriented
solutions
32
Strictly Confidential
Referentenentwurf des Bundesministeriums des Innern
Source: Kabinettsentwurf Januar 2017 (BMI).
Entwurf eines Gesetzes zur
Anpassung des
Datenschutzrechtes an die
Verordnung (EU) 2016/679
und zur Umsetzung der
Richtlinie (EU) 2016/680
(Datenschutz-Anpassung-
und Umsetzungsgesetz EU
DSAnpUG-EU)
A. PROBLEM UND ZIEL
Am 25. Mai 2018 wird die Verordnung (EU) 2016/679 des Europäischen Parlaments und des
Rates vom 27. April 2016 zum Schutz natürlicher Personen bei der Verarbeitung
personenbezogegen Daten, zum freien Datenverkehr und zur Aufhebung der Richtlinie 95/46/EG
(Datenschutz-Grundverordnung) (ABI. L 119 vom 4.5.2016, S.1) unmittelbar geltendes Recht in
allen Mitgliedstaaten der Europäischen Union sein. Ziel der Verordnung (EU) 2016/679 ist ein
gleichwertiges Schutzniveau für die Rechte und Freiheiten von natürlichen Personen bei der
Verarbeitung von Daten in allen Mitgliedstaaten (Erwägungsgrund 10). Der Unionsgesetzgeber
hat sich für die Handlungsformen einer Verordnung entschieden, damit innerhalb der Union ein
gleichmäßiges Datenschutzniveau für natürliche Personen gewährleistet ist (Erwägungsgrund
13). Die Verordnung (EU) 2016/679 sieht eie Reihe von Öffnungsklauseln für den nationalen
Gesetzgeber vor. Zugleich enthält die Verordnung (EU) 2016/679 konkrete, an die
Mitgliedstaaten gerichtete Regelungsaufträge. Daraus ergibt sich gesetzlicher Anpassungsbedarf
im nationalen Datenschutzrecht.
33
Strictly Confidential
Questions for discussion
What will be the first▪ «Uber moment» in Digital Healthcare?
Will IT companies become the most innovative pharma companies or vice versa?▪
Will IT companies become the best health care insurance companies?▪
Which new▪ “convergent” business models and cooperation between pharma, healthcare and IT
are possible, in particular in Germany and Europe?
Who pays for what and who earns the▪ money?
Where▪ is the patient?
34
Strictly Confidential
Summary
▪ New business models and cooperations among different industries, payers, patients and healthy
people are mandatory for success.
▪ A balanced individual/personalized access and public anonymized access to R&D, clinical data,
health records, social media, health insurance data and open architecture is the key to success.
▪ Big returns on Digital Health investments takes more time as „big“ success is linked to
development time lines of novel products/services in Life Science and Healthcare.
▪ Convergence of data protection and data security legislation are necessary.
▪ Veracity and validity of data in Digital Health applications and outdated data silos remain a
challenge.
35
Strictly Confidential
USA
BOSTON
1 GRANT STREET,
SUITE 400 FRAMINGHAM, BOSTON,
MA, 01702 USA
TEL +1 (774) 777 5255
BOSTON@ALIRAHEALTH.COM
SPAIN
CASAFRANCA 38,
08017 BARCELONA, SPAIN
TEL +34 (93) 406 71 71
BARCELONA@ALIRAHEALTH.COM
FRANCE
31 RUE DE MONCEAU,
75008 PARIS, FRANCE
TEL +33 (0)1 44 54 96 23
FAX +33 (0)1 44 54 90 20
PARIS@ALIRAHEALTH.COM
ITALY
VIA CARLO OTTAVIO
CORNAGGIA 10,
20123 MILAN, ITALY
TEL +39 (02) 36680198
FAX +39 (02) 94 19 50 07
MILAN@ALIRAHEALTH.COM
GERMANY
KURFÜ̈RSTENSTRAßE 22,
80801 MUNICH, GERMANY
TEL +49 (89) 416 14 22-0
FAX +49 (89) 416 14 22-99
MUNICH@ALIRAHEALTH.COM
USA
SAN FRANCISCO
101 MONTGOMERY ST,
SUITE 2300, SAN FRANCISCO,
CA, 94104 USA
TEL +1 (774) 777 5255
SANFRANCISCO@ALIRAHEALTH.COM
THANK YOU VERY MUCH
FOR YOUR ATTENTION!
Dr. Martin Pöhlchen, Partner, Germany
martin.poehlchen@alirahealth.com
37
Strictly Confidential
Digital Health Trends (Panel I discussion)
▪ Hypothesis 1: The barrier between healthy beings and patients will become obsolete.
▪ Hypothesis 2: From monitoring only to diagnosis, prevention and treatment
▪ Hypothesis 3: Personalized medicine and longitudinal studies become standard.
▪ Hypothesis 4: From “wellness” tracking to medical grade devices
▪ Hypothesis 5: From “classic” wearables to ingestible, transdermal and implantable
sensors/medical devices and combinations
Synchronizing HealthcareBerenberg Bank & Goldman Sachs
German Corporate Conference, Munich
Christian B. Teig, CFO
24 September, 2013
10th DVFA Life Science Conference 2017
The Telematics Infrastructure
The Coming eHealth Revolution in Germany
Christian B. Teig, CFO
Frankfurt
13th June, 2017
The coming secure communication arena in German healthcare
Source: gematik
10th DVFA Life Science Conference 201713/06/20172
The Telematics Infrastructure is based on the eGK
The purpose of the German “Electronic Health Card” (eGK) is to improve
the medical care of patients
The eGK shall ensure that all healthcare providers have immediate
access to all necessary medical information to deliver high quality and
cost efficient care
10th DVFA Life Science Conference 201713/06/20173
Gematik GmbH is behind the eGK / TI roll-out
Facts
Founded in January 2005
Owned by the 15 top organizations of the German health system (e.g.
Bundesärztekammer, DAV - Deutscher Apothekerverband, Deutsche
Krankenhausgesellschaft, GKV-Spitzenverband, KBV - Kassenärztliche
Bundesvereinigung)
Working closely with the Federal Ministry of Health
Tasks
Defining withing technical specifications for components, services and
applications to be used in the Telematics Infrastructure
Introduction, maintenance and enhancement of
eGK
electronic prescriptions
and additional applications
10th DVFA Life Science Conference 201713/06/20174
Realizing the Telematics Infrastructure has been a long process
2001
2003
Lipobay
scandal
2005
Introduction of eGK
by 1.1.2006 written
into German Law
EU tender
„bIT4health“
Foundation of
Gematik GmbH
GesKVO
„Plan B“
2006
North Rhine-
Westphalia eGK
pilot region
2009 2010
Rössler at
CeBIT: eGK is coming!
2012
Telematics
Infrastructure
tender process
10th DVFA Life Science Conference 201713/06/20175
The largest IT project ever in German healthcare
A total of 9 EU-wide tender processes have been completed:
Online Rollout Level 1 (ORS-1): Testing of the Telematics Infrastructure in 2 test regions, each
with 500 providers (doctors, dentists and hospitals). 3 contracts awarded through EU-wide
tenders:
LOS 1: Construction and operation of decentralized components and necessary infrastructure services;
testing in Region South-East (Award: T-Systems)
LOS 2: Construction and operation of decentralized components and necessary infrastructure services;
testing in Region North-West (Award: Booz/CGM/KoCo consortium)
LOS 3: Construction and operation of the central services and infrastructure surroundings for the
Telematics Infrastructure (Award: Arvato Systems)
G2 Cards: 5 contracts for a new generation of chip cards awarded through EU-wide tenders:
LOS 1 & 2: Card Operating System (COS) for all card systems: eGK, HBA, SMC-B, gSMC-K and gSMC-KT
(Awards: Giesecke & Devrient, T-Systems)
LOS 3 & 4: Production of all relevant cards to be used in the ORS-1 test regions: eGK, HBA, SMC-B, gSMC-
K and gSMC-KT (Awards: Bundesdruckerei, T-Systems)
LOS 5: PKI infrastructure and associated services for Card Verifiable Certificates (Award: Atos)
Scientific evaluation: 1 contract awarded through EU-wide tender for scientific evaluation of
the two ORS-1 test regions (Award: Friedrich-Alexander-Universität)
10th DVFA Life Science Conference 201713/06/20176
Tender process for 2 pilot regions (ORS-1)
December 11
Gematik reaches a
new decision to
test the Telematics
Infrastructure
May 12
Bidder Contest
October 12
Confirmation of five
qualified vendors
for the final offering
November 12
Publication of
specifications and
request for final
offers
Tender process
10th DVFA Life Science Conference 201713/06/20177
Two contracts were awarded in December 2013
November 13
Deadline for final
offers
December 13
Acceptance of
tender for two
partnerships
2014/2015
Test of the
Telematics
Infrastructure and
Evaluation
2016 (est)
Start of the rollout
of the Telematics
Infrastructure
Tender process
Winners announced 3 December 2013:
Region North-West1: Booz / CGM / KoCo consortium
Region South-East2: T-Systems
1: Schleswig-Holstein, Nordrhein-Westfalen, Rheinland-Pfalz
2: Sachsen, Bayern
10th DVFA Life Science Conference 201713/06/20178
Project scope of ORS-1
Construction and operation of decentralized components and necessary infrastructure
services:
Phase 1: Insured Master Data Management (VSDM)
Phase 2:
Qualified Electronic Signature (QES)
Secure communication between healthcare providers (KOM-LE)
Tasks
Planning and conception
Recruit providers to participate in the pilots: Doctors (375), Dentists (125), Hospitals (5)
Build a central VPN-access service and ensure its operations
Develop, test and certify the necessary decentralized components (Konnektor (1x), Card
terminals (10x ))
Update and integrate existing doctor, dental and hospital software applications with the
Telematics Infrastructure (13x)
Rollout, service und support of the decentralized components for about 3 years
10th DVFA Life Science Conference 201713/06/20179
The most important parties/products
10th DVFA Life Science Conference 201713/06/201710
The full scale pilot in the Northwest region
was launched in December 2016.
All test installations have been
successfully connected, more than 550,000
tests of the insured master data (VSDM) have
been successfully carried out and information
on more than 125,000 electronic health cards
have been updated in real time.
As a result, CGM has exceeded the project target of half a million online card tests
more than two months before the end of the trial period.
The installations and pilot operation are running without any material problems.
Based on the successful results, gematik declared last week the Telematics
Infrastructure to begin live operation 1 July 2017
Despite many delays and revised planning scenarios, the goal is still to have the
nation-wide roll-out completed by 1 July 2018 as required by the eHealth law
Current status
11 13/06/2017 10th DVFA Life Science Conference 2017
Parallel to the gematik project, the German federal Ministry of Health began in
2014 the preparation of a new bill – “The eHealth Law” (Gesetzes für sichere
digitale Kommunikation und Anwendungen im Gesundheitswesen)
With clear majority, the bill was approved in the Bundestag on December 3rd
2015 and the new law became effective January 1st 2016
The eHealth law contains clear
deadlines and financial
incentives/penalties to ensure
the timely roll-out of the
Telematics Infrastructure in
healthcare all over Germany
in the 2016-2018 timeframe
The German eHealth Law
10th DVFA Life Science Conference 201713/06/201712
Rollout timeline in the eHealth law
1.1.2016
30.06.2016
The Law
comes into
force
1.1.2018
* If the deadline is not met, from 2017 on the expenditure in the budgets of the GKV SpiBu and the KBV must not
exceed the expenditure of 2014 minus 1% each year until the action is performed
(1% = app. 100 mio €)
All pre-conditions for
roll-out of VSDM must
be in place*
Nation-wide roll-out of the
Telematik Infrastructure has to
be completed*
1.7.2018
Doctors’ compensation will be reduced by flat
rate of 1% if they are not using VSDM.
10th DVFA Life Science Conference 201713/06/201713
VSDM (eligibility check and update of insurance data) is the core service of the Telematics
Infrastructure.
Emergency Data Set (blood type, chronic diseases, allergies etc.) stored on the electronic
health card. Service must be available beginning 2018. Doctors who create and maintain such
datasets on behalf of patients will be compensated (no amount given)
Medication plan (for patients with more than 3 current prescriptions). Service must be
available from October 2016 in paper form and then in the ‘medium term’ (Mittelfristig) be
available over the electronic health card.
Electronic letters (Medical reports, referrals and discharge letters between ambulatory
doctors and hospitals). Doctors get an incentive of 55 cents per medical report sent
electronically and 50 cents per discharge letter received electronically in 2016 and 2017.
Hospitals get 1 Euro per discharge letter sent electronically from 1 July 2016. From 2018, the
incentives for electronic letters will only be paid if the transmission is done over the
telematics infrastructure (no amount given).
Telemedicine. Electronically transmitted radiology reports will be compensated beginning
1 April 2017 (no amount given). The regions also has the mandate to consider additional paid
telemedicine services.
Services prescribed in the eHealth law
10th DVFA Life Science Conference 201713/06/201714
Potential additional products and services
Nr. Product / Service Customer / User Source
1 Elektronischer Entlassbrief Krankenhaus eHealth Law
2 Konsiliarische Befundbeurteilung Ärzte eHealth Law
3 Notfalldatensatz Zahnärzte eHealth Law
4 Arzneimitteltherapiesicherheit (AMTS) Ärzte / Apotheke eHealth Law
5 Medikationsplan Ärzte / Apotheke eHealth Law
6 Sicher Übermittlung elektronischer Briefe Ärzte / Krankenhaus eHealth Law
7 Organsspendeausweis Krankenhaus gematik
8 Elektronische Fallakte Ärzte / Krankenhaus gematik
9 Elektronisches Patientenfach Ärzte / Krankenhaus gematik
10 Elektronische Patienttenquittung Ärzte / Krankenhaus / Zahnärzte gematik
11 Fachdienst VSDM Telematik Infrastruktur gematik
12 VPN-Zugangsdienst Telematik Infrastruktur gematik
13 Patientenverfügung Ärzte / Krankenhaus CGM
14 Impfstatus und Impfplanung Ärzte CGM
15 Zahnstatus Zahnärzte CGM
16 Ernährungsplan Ärzte CGM
17 Elektronische Patientenakte Ärzte / Krankenhaus CGM
10th DVFA Life Science Conference 201713/06/201715
Potential additional products and services (2)
Nr. Product / Service Customer / User Source
18 Laborbefund Ärzte / Krankenhaus CGM
19 Röntgenbefund Ärzte / Krankenhaus CGM
20 AU - Bescheinigung Ärzte CGM
21 KH Einweisung Ärzte / Krankenhaus CGM
22 Heil- und Kostenplan Zahnärzte CGM
23 .. weitere Formulare Ärzte / Krankenhaus CGM
24 One-Klick Abrechnung (der KBV) Ärzte CGM
25 Zuzahlungsinformationen Ärzte / Krankenhaus / Zahnärzte CGM
36 Teilnahme an Selektivverträgen Ärzte / Krankenhaus CGM
27 Arzneimittelkonto Ärzte / Krankenhaus CGM
28 Software Assisted Medicine - Diabetes Ärzte / Krankenhaus CGM
29 Software Assisted Medicine - Herzinsuffizienz Ärzte / Krankenhaus CGM
30 Software Assisted Medicine - Rückenschmerz Ärzte / Krankenhaus CGM
31 Software Assisted Medicine - Depression Ärzte / Krankenhaus CGM
32 Software Assisted Medicine - Rauchentwöhnung Ärzte CGM
33 Software Assisted Medicine - Gesundes Gewicht Ärzte / Krankenhaus CGM
34 Software Assisted Medicine -
Blutdruckstabilisierung Ärzte / Krankenhaus CGM
10th DVFA Life Science Conference 201713/06/201716
1.346
1.497
1.517
1.531
1.540
1.577
1.582
1.605
1.614
1.674
1.684
1.695
1.752
1.768
1.781
1.806
1.844
1.848
1.851
1.876
1.916
1.972
2.010
2.071
2.087
2.121
2.133
2.158
2.167
2.490
Lithuania
Latvia
Slovakia
Malta
Poland
Slovenia
Cyprus
Greece
Luxembourg
Czech Republic
Hungary
Romania
Bulgaria
Belgium
Germany
Turkey
Portugal
Hungary
Ireland
France
Iceland
Italy
Sweden
United Kingdom
Finland
Netherlands
Estonia
Norway
Spain
Denmark
13/06/2017 10th DVFA Life Science Conference 201717
The EU scorecard for Healthcare IT
Source: Benchmarking Deployment of eHealth among General Practitioners (2013) – European Commission
Composite index of IT adoption by country
Data center B
13/06/2017 10th DVFA Life Science Conference 201718
The Danish Health Data Network (SDN) and VANS network
User User User User User User User User
Secured connections between secured local
networks
Datacenters owned by MedCom,
operations outsourced by EU tender
(currently Netdesign A/S)
MPLS
Internet
VPN
Fixed lines
Secure messaging (EDI) via
private VANS operators KMD or
Highjump
Data center A
KMD HighJump
Evolution of services in the network
19
2001
2003
The “Good EDI
letter” defined
by MedCom
2005
Sundhed.dk – the
Danish eHealth
portal
Citizens’ access to
their own
prescriptions
EDI becomes XML
‚e-journal‘ -wider
access to journal
data for citizens
2007
Telemedicine is
deployed nationwide
2009
2011 2014
Shared
Medication
Record (FMK)
New standards
HL7 - IHE
13/06/2017 10th DVFA Life Science Conference 2017
13/06/2017 10th DVFA Life Science Conference 201720
Evolution of GP electronic communication
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
92 93 94 95 96 97 98 99 20 01 02 03 04 05 06 07 08 09 10 11 12
E-Prescriptions = 90 %
Disch Letters = 100 %
Lab reports = 100 %
Lab test Orders = 100 %
E-Referrals = 95 %
MedCom Messages / Month (in million)
+6000 doctors, pharmacies, municipalities and hospitals
65 IT vendors
6 milllion messages/month
15% growth/year
70-90% of all documents
Source: MedCom
13/06/2017 10th DVFA Life Science Conference 201721
Denmark’s e-Health portal introduced in 2003
Online Electronic Health Record
from hospitals
Cross-sectorial personal electronic
medicine profile
Overview of personal medical
history since 1977 (list of contacts
with hospitals)
Overview of contact with primary
sector clinics since 2003
Online organ donor registration
’My log’ (lets the patient see which
health professionals have accessed
their personal data)
13/06/2017 10th DVFA Life Science Conference 201722
FMK – Shared medication data base from 2014
13/06/2017 10th DVFA Life Science Conference 201723
Norsk Helsenett (Norwegian Health Network)
Rolled out nationwide in 2006-2007 to all doctors and hospitals
Transformed to a state-owned enterprise in 2009, owned by the Ministry of health and care
services
Runs as a government monopoly with approximately 150 employees
Backbone network, operations, support and consultancy services are mostly subcontracted
through EU tenders
In addition to all healthcare providers, the network is also open to about 100 connected,
third-party service providers (hereunder CGM)
All activity is governed by the «Code of Conduct for information security in the healthcare,
care, and social services sector»
13/06/2017 10th DVFA Life Science Conference 201724
Sjunet (Swedish Health Network)
Since 1998 the Sjunet
application has been
connected to virtually all
Swedish hospitals and
Primary Care Centres
Sjunet is offered by Inera AB
Inera is a common service
provider for county councils
in Sweden
3 ways to connect to Sjunet:
Dedicated fixed line from
Inera
3rd party local network
connected to Sjunet
IPSEC-encrypted VPN-
connection via Internet
Austria and Germany have similar eHealth strategies
25
Political discussions from 2003
ELGA GmbH
e-card
GesundheitsInformationsNetz
GINA-Box
eHealth law 2012
E-Medikation
….etc…..
13/10/2017 10th DVFA Life Science Conference 2017
Political discussions from 2001
gematik GmbH
eGK
Telematik Infrastruktur
Konnektor
eHealth law 2015
Medikationsplan mittels eGK
….etc….
13/06/2017 10th DVFA Life Science Conference 201726
Where we stand
Germany is late w.r.t. eHealth
So is Austria
More pragmatic technology and security solutions have enabled the healthcare
economies in Scandinavia to become networked 10-20 years ago
However, many issues related to identification, authentication and authorization
remain unresolved in these early countries
Based on the eGK and Telematics infrastructure, Germany now has an excellent
opportunity to leapfrog to the forefront of eHealth
The next 3 years will see a late but powerful eHealth revolution in Germany
There is reason to be optimistic!
10th DVFA Life Science Conference 2017
Thank you for your attention!
CompuGroup Medical SE
Investor Relations
Maria Trost 21
56070 Koblenz
www.cgm.com
Phone: +49 (0) 261 8000-6200
Email: investor@cgm.com
13/06/201727
May	2017│Confidential
Investor	Presentation
Page	2
D i s c l a i m e r
This	confidential	document	and	the	information	contained	in	this	document	(the	“Presentation”)	constitutes	neither	an	offer	for	sale	or	subscription nor	a	
solicitation	of	a	purchase	or	subscription	order	for	Cellnovo shares	in	any	country.	No	offer	of	shares	is	made,	or	will	be	made	in	France,	before	obtaining	a	
visa	from	the	Autorité des	Marchés Financiers (the	“AMF”)	on	a	prospectus	comprising	a	registration	statement	(document	de	base)	and	securities	note	
(note	d’opération)	that	will	be	submitted	to	the	AMF.
In	particular,	this	Presentation	does	not	constitute	an	offer	for	sale	of	securities	or	any	solicitation	of	a	purchase	or	subscription	order	for	securities	in	the	
United	States	or	by	U.S.	persons	(as	such	terms	are	defined	in	Regulation	S	under	the	U.S.	Securities	Act	of	1933,	as	amended (the	“Securities	Act”).		
Cellnovo shares	may	be	only	offered	or	sold	in	the	United	States	pursuant	to	an	effective	registration	statement	under	the	Securities	Act	or	under	an	
exemption	from	the	registration	requirement	of	the	Securities	Act.	Cellnovo shares	have	not	been	and	will	not	be	registered	under	the	Securities	Act,	and	
Cellnovo has	no	intention	of	making	any	public	offering	of	its	shares	in	the	United	States.
This	Presentation	does	not	constitute	a	prospectus	within	the	meaning	of	Directive	2003/71/EC	of	the	European	Parliament	and	of	the	Council	of	
November	4,	2003,	as	amended,	in	particular	by	Directive	2010/73/EC	of	the	European	Parliament	and	of	the	Council	of	November 24,	2010	(the	
“Prospectus	Directive”).	Its	dissemination	may	be	governed	by	specific	regulations	in	certain	countries.	Persons	in	possession	of	this	Presentation	should	
therefore	acquaint	themselves	and	comply	with	any	local	restrictions.
No	action	has	been	taken	or	will	be	taken	for	the	purpose	of	enabling	a	public	offering	of	securities	requiring	the	publication	by	Cellnovo of	a	prospectus	in	
a	Member	State	other	than	France.	Consequently,	the	Cellnovo shares	may	not	and	will	not	be	offered	in	any	Member	State	other	than	France,	except	in	
accordance	with	the	exceptions	set	forth	in	Article	3.2	of	the	Prospectus	Directive	or	in	other	cases	not	requiring	publication	by	the	Company	of	a	
prospectus	pursuant	to	Article	3.2	of	the	Prospectus	Directive	or	other	applicable	regulations	in	that	Member	State.
Regarding	the	United	Kingdom,	this	Presentation	has	not	been	approved	by	an	authorised	person	in	accordance	with	Section	21	of	the	Financial	Services	
and	Markets	Act	2000	and	therefore	it	is	intended	to	be	delivered	solely	and	for	information	purposes	only	to	persons	who	(i)	are	investment	professionals	
within	the	meaning	of	Article	19(5)	of	the	Financial	Services	and	Markets	Act	2000	(Financial	Promotion)	Order	2005	(as	currently	in	effect,	hereinafter	the	
“Financial	Promotion	Order”),	(ii)	are	referred	to	at	Article	49(2)	(a)	to	(d)	(“high	net	worth	companies,	unincorporated	associations,	etc.”)	of	the	Financial	
Promotion	Order,	(iii) are	outside	the	United	Kingdom,	or	(iv)	are	persons	to	whom	an	Presentation	or	incitement	to	engage	in	investment	activities	(within	
the	meaning	of	section	21	of	the	Financial	Services	and	Markets	Act	2000)	in	the	context	of	the	issuance	or	disposal	of	securities	may	legally	be	extended,	
directly	or	indirectly	(all	such	persons	being	collectively	named	“Authorised	Persons”).	This	Presentation	may	not	be	used	by	any	person	who	is	not	an	
Authorised	Person.	By	accepting	this	Presentation	and	not	immediately	returning	it,	the	recipient	represents	and	warrants	that	they	are	a	person	who	falls	
within	the	above	description	of	persons	entitled	to	receive	the	Presentation.
Page	3
A M a n a g e m e n t Te a m W i t h A S u c c e s s f u l Tr a c k R e c o r d
Dr.	Sophie	Baratte
CEO
l 20	years	experience	in	Sales	&	Marketing	functions	in	the	medical	technology	sector,	including	Sorin	Group
l Served	as	CEO	of	CIT,	General	Manager	for	the	In	Vitro	Diagnostics	branch	of	Johnson	and	Johnson	in	France	
and	senior	EMEA	Sales	&	Marketing	Director	for	Lifecell
Engineer,	PhD	in	biotechnology	and	MBA
Erwan	Martin
CFO
l 20	years	experience	in	finance	and	in	biotechnologies
l Former	CFO	of	Genomic	Vision,	co-founded	Cytomics	Pharmaceuticals,	served	as	project	manager	at	Syndex	
Julian	Shapley
CSO,	Founder
l NASA	experience
l Founder	of	Cellnovo	since	2008
MBA	at	Warwick	Business	School
Ph.D.	in	micro-fluidics	at	Cardiff	University
John	Brooks
Chairman	
l Serverd	as	CEO	and	Founder	of	Insulet
l and	as	CEO	of	Joslyn	Diabetes	center
l Over	30	years	of	experience	in	the	medical	device	industry	in	diabetes
Javaid	Masoud
CTO
l Served	at	Medtronic	and	at	Sorin	Group	in	Senior	director	roles,	for	wireless	technologies,	embedded	firmware	
development	for	implantable	cardiac	defibrillators,	wireless	communication	protocol,	embedded	firmware	for	
implantable	devices,	and	software	for	external	instruments
Page	4
C e l l n o v o i n a N u t s h e l l
• Cellnovo	develops	and	commercialises	a	disruptive	Insulin	Micro-pump
• A	$2.5Bn	market:	growing	and	well	reimbursed	
Focused	on	Type	1	diabetes with	potential	for		larger	Type	2	market	
• Addressing	clear	market	needs
The	only	real	time	data	device,	for	better	patients	outcome
• Unique	Accuracy	and	Safety	features
• A	clearly	defined	global	strategy	supported	by	strategic	partners	
- Roche:	contract	for	Blood	Glucose	Measurement	
- Flex:	manufacturing	partner
- Air	Liquide:	major	distribution	partner
• Road	map	towards	Artificial	Pancreas	and	smartphone
• IPO	on	Euronext	Paris	on	July	2015:	€32.4m	raised	to	date
• Private	placement	of	€5.4m	achieved	in	Q3	2016
The	First	Connected	All-in-one	Diabetes	Management	System
1.	North	America+	Main	European	countries,	Medtronics,	Investor	Conference,	June	2014
Page	5
• Informing	payers	of	compliance	to	
treatment
• Lower	pricing	than	other	Wearable	
pumps
C e l l n o v o , a b r e a k t h r o u g h i n I n s u l i n D e l i v e r y, f o r a l l s t a k e h o l d e r s
Driving	Efficiency	
and	Better	Outcomes
Driving	Savings
• The	ultimate	wearable	pump
• Requested	by	patients
• E- connected	for	family’s	peace	of	
mind
• Real	time	information	to	drive	
Better	Patients	Outcomes
• The	un-equalled	accuracy	and	safety	
of	drug	delivery	in	micro-pumps
Cost	Effective	Patients	support
• Effective	patients’	communication	and	trouble	shooting,	
based	on	Real	time	back-end	data
Freedom	and	peace	of	mind
The	only	E-connected,	Accurate,	Wearable	insulin	pump
Page	6
A S t r o n g U p c o m i n g N e w s F l o w
20182017
Flex	industrialize	
Cellnovo	insulin	
cartridges
Q2 Q3 Q4
Commercial	
agreements	
with	AP	Type	
Zero
Diabeloop
enters	CE	
marking	clinical	
trial
New	
distribution	
partners
New	Blue	Tooth	
Android	System
510K	
clearance
Artificial	
Pancreas	filling	
of	CE	marking
First	sales	in	
the	US
CE	marking	of	
“Smartphone”
Connection	of	
Blue	Tooth	BGM
Type	Zero	
studies	in	the	US	
and	in	EU
Artificial	Pancreas	
commercialization	in	
the	EU
Cellnovo	completely	
outsources	
manufacturing
Connection	of	
CGM
New	food	
library
✔
✔ ✔
All	the	fundamentals	
in	place Huge	growth	and	introduction	of	more	breakthrough	technologies
Production
Product	
Development
Commercialization	
Artificial	
Pancreas
Timeline
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A	unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	8
Ty p e 1 : A l a r g e m a r k e t , w e l c o m i n g i n n o v a t i o n
T1	Patient	Market* MDI Tubed	Pump Micro	Pump
US	%	Patient	Use 70% 25% 5%
EU	%	Patient	Use 85% 12% 3%
Market Size $2	B $400	M
Growth	Rate <5% 40%
Market	Players
Pumps	are	providing	short	and	long	term	benefits	to	patients,	despite	low	penetration
*	company	estimates
Page	9
E a s y t o A c c e s s w i t h F a v o u r a b l e R e i m b u r s e m e n t
Cellnovo	micro-pump	has	access	to	public	funding	across	many	geographies
Market Durables 3	Day	disposables
USA $4,500 $15
UK £2,750 £11.30
France €2,340 €16.65
Italy €4,800 €18
Germany €2,800 €12
1.	Source	:	Company
Simple	market	access	based	on	Existing	codes
• Market	access	provided	by	CE	marking
o Already	CE	marked
• Market	access	provided	by	510K	Clearance
o Expected	end	of	2017
• Reimbursement using	traditional	pumps	codes
o Established	codes	in	each	countries
o Describing	a	durable	pump	and	a	consumable	
part
• Reimbursement using	CPT	code	1	
Tube	pumps’	prices
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A	unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	11
C e l l n o v o : A G a m e C h a n g e r f o r I n s u l i n P u m p Te c h n o l o g y
The	perfect	combination	between	a	new	generation	of	patch	pump	and	a	mobile	handset	
to	allow	the	best	accuracy	and	a	24/7	health	remote	monitoring
Intuitive	operation,	wireless	Internet	connectivity	and	real-time	tracking
=	all	industry	firsts
• The	insulin	reservoir
• Pumping	mechanism
• Occlusion	sensor	
• High	resolution,	full	colour	touch	screen
• GSM	Modem
• Micro	SD	port	
• Apps	friendly
• Roche	BG	Meter	integrated
• Bolus	calculator
• Real-time	data
• Automated	capture	of	data	
and	transmission
• Analytics	and	trends
• Stakeholders	access• Pump	microprocessors	and	
memory
• Rechargeable	battery
• Accelerometer
• Precision	reservoir	sensor
Insulin Cartridge
Mobile
Handset
Online
Wireless
DurablesDisposables
Page	12
C e l l n o v o B e n e f i t s c o m p a r e s p o s i t i v e l y t o t h e o t h e r m i c r o - p u m p s
for	Additional	
Comfort
Better	Outcome	
and	Peace	of	Mind
Better	COGS	
and	Eco-friendly	Device
High	Quality	of	
Treatment
A	Key	Feature	for	All
Intuitive	Usage
E-Health	in	real	time
Higher	Accuracy	of	
delivery
Disposable	plastics
Detachable
Enhanced	Safety
Touch	Screen	Color	
Handset
Page	13
C e l l n o v o , t h e d a t a s o l u t i o n f o r b e t t e r o u t c o m e
CLINIC	&	
CLINICIANS
PATIENTS’
FAMILIES PAYER
Reducing	pressure	
on	National	Health	
Systems’	resources
Peace	of	Mind	with	no	
intrusion	in	patients’	life	
with	apps	and	portal	
access
• Informs	and	Guides	the	
patients
• Informs	the	family
• Generates	bespoke	
alarms	on	Family’	
Smartphones
Increasing		Efficiency	and	
Generating	better	
outcomes
• Prioritization	of	treatments
• Cost	reduction
• Productivity
• Reactivity
• Cost	reduction
• Care	improvement
• Reduction	of	
complications
• m-health:	modernized	
healthcare	system
AND	PARTNERS
• Informed	trouble	shooting	calls
• Easy	logistics
Page	14
C e l l n o v o s y s t e m i s m o s t a c c u r a t e p a t c h p u m p i n d r u g d e l i v e r y
Not	all	micro-pumps	are	equal
Cellnovo:	2	part	pumping	system
-100,0%
-50,0%
0,0%
50,0%
100,0%
0 50 100 150 200
Flow	rate	error
Observation	duration	(minutes)
Omnipod
Percentage	error	vs.	observation	window	(Time	based).
-100,0%
-80,0%
-60,0%
-40,0%
-20,0%
0,0%
20,0%
40,0%
60,0%
80,0%
100,0%
0 50 100 150 200
Flow	rate	error
Observation	duration	(minutes)
Cellnovo
Percentage	error	vs.	observation	window	(Time	based).
Cardiff	University,	UK- Jenna	L	Bowen	and	Chris	J	Allender - Trumpet	curves	for	a	typical	Cellnovo	and	OmniPod™	patch	pump	device	showing	the	maximum	positive	and	maximum	negative	flow	rate	
error	(green	solid	lines)	and	the	average	flow	rate	error	(red	dotted	line)	for	2,	5,	11,	19	and	31	pulses.	
o Accuracy	of	the	Wax-powered	
pumping	mechanism
o Superiority	of	durable	electronics	
and		Drop-by-drop	alterations	
control	system
A	difference	explained	by	the	design
Traditional	patch	pump:	fully	disposable,	all	in	
one	system
o Low	cost,	low	
sophistication	electronics
o Flat	rate	pumping	
mechanism
Page	15
A c c u r a c y, t h e r e s u l t o f a u n i q u e m e c h a n i s m o f d e l i v e r y
The	core	technology:	the	paraffin	wax	Micro-actuator	
The	expansion	of	
heated	paraffin	wax	
serves	as	mechanism	
to	push	a	piston	
against	a	membrane,	
thereby	creating	a	
pumping	mechanism
OCCLUSION	
VALVE
INLET	
VALVE
OUTLET	
VALVE
PUMPING	
CHAMBER GEARING	
PISTON
DIODE WAX
Cool	Wax Heated	Wax
After	
melting
+15%
Volumetric	
Expansion	
(%)
Solid	phase Liquid	phase
IP	protected	until	2035
Wax	Micro	Actuator
Displacement	
Sensor
Micro- Valve
Cyber	security
Page	16
S a f e t y s y s t e m s o n b o a r d
Product	 Time	to	Occlusion	Alarm Missed	Insulin	(U)
Cellnovo 24.12 2.02
Omnipod	Gen2 41.35 3.46
Medtronic 57.49 4.82
Animas	Vibe 44.09 3.68
Roche	Spirit	Combo 28.47 2.39
Best	in	class	in	case	of	occlusion
Intelligent	Delivery	SystemDelivery	Sensor
Automatic	release	mechanism
Temperature	risk	alarm
Insulin	delivery	alarms
72-hour	Expiry	alarm
Encryption
The	pump’s	electronics,	to	bring	safety	to	a	new	level
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A	unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	18
C o n s u m a b l e : l a r g e s c a l e p r o d u c t i o n w i t h F l e x
• High	volume	automation	and	
manufacture
• Stacked	basic	components,	
suitable	for	high	cavity	moulding
Flextronics’	Mass	productionCellnovo’s Limited	production
NowUntil	Q2	2017
IC	capacity Per	production	line
Capacity pa 650,000
IC	capacity 2015
Capacity pa 50,000
From	Cellnovo’s R&D	workshop
To	flex	Austria	in		Q2	2017
Followed	by	producing	in	a	low	labor	cost	country	in	Q1	2018.	
Design	to	cost	to	further	optimize	COGS1 2 3 4
1
2
3
4
Increasing	volumes	of	consumable	parts
Reducing	COGS
Page	19
D u r a b l e e l e m e n t s : a s i m p l e p r o d u c t i o n r o a d m a p
The	mid-term	manufacturing	strategy	favors	Outsourcing
Cellnovo	to	remain	lean	with	low	Overheads	
Relatively	low	production	volumes	are	required:	each	patient	needs	2	pumps	and	1	handset
The	manufacturing	roadmap	will	aim	at	decreasing	COGS	by	2	folds	by	mid	2018
2018	:	
Replaced	by	a	smartphone	tablet
2017-mid	2018:	
Assembled	by	Cellnovo
Production	strategy
2017:	
Assembled	by	Cellnovo
• PCB	made	by	Sony
The	Micro-Pump
The	Handset
Mid-2018:	
outsourced
*
*	Picture	non-contractual• PCB	made	by	Sony
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	21
C e l l n o v o ’ s c o m m e r c i a l r o a d m a p
A	network	with	direct	sales	forces	and	experienced	distributors
Objective	2020	horizon:	45,000	patients
2014
System	introduction	through	proprietary	sales	force	
in	the	UK	and	France	
2016
Expansion	into	other	major	European	countries	using	
specialized	distributors	:	Netherlands,	Italy
2017
Expansion	into	Spain,	Ireland,	Greece,	Israel,	..	
2016
510k	submission
2017
Launch	in	the	US
Launch	in	Canada
First	countries	in	L.A.
2017	
Launch	in	Australia/NZ
Launch	in	Hong	Kong
2018
Launch	in	India
2019/2020
Launch	in	China
Europe USA China/Asia
Direct	Distribution	(UK,	France)
Air	Liquide	Santé	network:	Benelux,	Italy
Expansion	to	new	European	countries
Page	22
C e l l n o v o U S S t r a t e g y
Targeted	launch	
Q4	2017	– Q2	2018
• Targeting	main	KOL
• Regional	complementarity
• Payers	complementarity
Objective:	demonstrate	the	business	case
Patients’	preference	/	Payers’	acceptance	/		E-health	benefits
• Light	structure	to	guarantee
o Leadership
o Sales	
o Training
o Marketing
o H&E
US	National	launch	
Q3	2018
• Through	an	established	partner
Benefits
Price
Cellnovo	will	reinforce	the	distributor	effort	by	putting	in	place	its	own	organization
5	Main	Cities Cellnovo	Structure Pricing	Strategy
2	to	3	Distributors
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A	unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	24
C e l l n o v o , t h e s y s t e m o f c h o i c e f o r A r t i f i c i a l P a n c r e a s
• US	Well	proven	program,	with	215,501	hours	of	
clinical	trial
• Data	on	30	patients	“80%	of	hours	on	target”
• CE	marking	early	2018,	followed	by	EU	launch
• “Natural”	EU	partner
o Commercial	contract	pending	
• WW	commercial	license	agreed
• Integration	of	the	product	on-going
• Clinical	studies	in	discussion
• Best	placed	US	partner
All	projects	with	Dexcom G5
• French	atomic	center	mathematicians		and	12	major	
teaching	hospitals	in	France	
CONTINUOUS
GLUCOSE
SENSOR
CONTROL
ALGORITHM
• Automatic	adjustments	of	the	
insulin	delivery
• Based	on	expert	Software	and	
Continuous	Blood	Glucose	reading
• Un-Equaled	Quality	of	Life
• Less	Deadly	Complications
The	potential	to	be	N1	Artificial	Pancreas	using	a		
Micro	pump	
Artificial	Pancreas,	the	next	break	through	in	Diabetes	management
Cellnovo	‘s	partners Commercial	strategy
Page	25
C o m p a r i s o n Ty p e Z e r o / M e d t r o n i c
• Founded	in	2005,	spin-off	from	UVA
• In	clinical	trials	since	2011
• The	most	published	Artificial	Pancreas	
SW
• Well	financed	by	the	NIH	
• CGM:	G5	Dexcom
Type	Zero,	a	Strong	partner
TypeZero
inControl
Medtronic	PID-IFB
Paper
Ly,	Buckingham	et	al
Diabetes Care,	2016
Ly,	Buckingham	et	al
DT&T,	2016
Control
24/7 – 85	days	and	
nights
Overnight	only	– 55	
nights
Average	BG	
Overnight
128	mg/dl 132	mg/dl
Overnight	
time within	
70-180	mg/dl
90.3% 79.9%
Overnight	
time	within	
70-150 mg/dl
76% 66.4%
Overnight	
time	below	
70	mg/dl
1.4% 5.4%
24/7	time	
within	70-
180 mg/dl
78.6% n/a
24/7	time	
below	70	
mg/dl
1.8% n/a
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A	unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	27
K e y F i n a n c i a l s o f t h e G r o u p - S a l e s
• 667	systems	shipped	in	total	since	launch	with	38	new	systems	in	Q1	2017
• Production	Capacity	of	Insulin	Cartridges	constrained	at	50,000	per	year	before	the	transfer	to	Flex
• On	April	2017,	Flex	has completed	the	first	commercial	batch	of	consumables	for	its	diabetes	management	system.
Annual Quarterly	– 3	months
2016 2015 Q1	2017 Q1	2016
Sales	(in	
Euros)
1,416,744 608,125 185,592 435,209
At	full	capacity,	the	Flex’s	production	line	is	able	to	produce	600,000	insulin	cartridges	per	year.
• A	cash	position	of	€5,8	million	at	March	31,	2017
• Cellnovo	is	in	the	final	stage	of	securing	a	Loan	facilities	with	a	first	draw	down	of	at	least	€5M.
Strong	2016	sales	growth	/	Sales	constrained	in	Q1	2017	by	limited	production	capacity
Page	28
K e y F i n a n c i a l s o f t h e G r o u p – P & L
Simplified	P&L	in	K€	– IFRS FY2016 FY2015
Revenues
Sales 1,419 609
Operating	expenses	
o/w	Costs	of	production (6,647) (5,845)
o/w	Research	and	Development (2,366) (3,244)
o/w	Sales	&	Marketing (2,545 (1,557)
o/w	General	&	Administration (4,476) (5,135)
Total Operating	Expenses (16,034) (15,781)
Other	operating	income	and	expenses 2 551
Operating profit / (loss) (14,614) (14,622)
Financial	result (559) (969)
Income	tax 625 1,126
Net	profit/(loss) (14,549) (14,464)
Page	29
C e l l n o v o o n t h e m a r k e t
Shareholding	structure	as	of	September	30th 2016
Financial	calendar
• Market	listed	on	Euronext	(Euronext	Paris)
• Share	price:	€5,3	(April	30th,	2017)
• Number	of	shares:	12,070,597		(March	31th
,	2017)
• Market	Cap:	€64	million	(April	30th
,	2017)
Stock	market	information
Events Date
2016	FY	sales Tuesday	January	31,	2017
2016	FY	results	and	2017	Q1	sales Wednesday	April	26, 2017
2017	H1	sales Tuesday	July	25,	2017
2017	H1	results Wednesday	September	27,	2017
2017	Q3	sales Tuesday October 31, 2017
Board	of	Directors
• John	Brooks,	Chairman	
• Sophie	Baratte, CEO
• Julie	Drapier, Aliad
• Marie	Landel, Independent
• Sofia	Loannidou,	censor, Edmond	de	Rothchild I.P.
• Raj	Parekh, Advent	Venture	Partners
• Holger	Reithinger, Forbion	Capital	Partners
• Rémi Soula, Independent
• Raphael	Wisniewski, Edmond	de	Rothchild I.P.
Forbion
14,5%
EDRIP
14,3%
Healthcare	
Ventures
9,4%
Advent	
International
9,4%
NBGI
5,5%
Omnes	Capital
4,1%
Air	Liquide	
Investissement
3,5%
Autres
39,4%
Others
Agenda
1. Positioned	on	a	fast	growing,	
accessible	market
2. A unique	technology
3. A	company	well	placed	on	
COGS
4. An	aggressive	commercial	
strategy
5. The	next	breakthrough:	the	
Artificial	Pancreas
6. Financials
7. Conclusions
Page	31
C e l l n o v o ’ s K e y S e l l i n g P o i n t s
Completed	
since	the	IPO	
✔
✔
✔
✔
Breakthrough	technology	on	a	high	growth	market	
Cost	advantages	over	current	wearable	pumps
Real	time	data	for	Patients	and	HCP	benefits
US	market	entry	by	end	2017	
Patients	superior	comfort	of	use	
First	Artificial	pancreas	on	the	market	early	2018
Set	for	large	scale commercialisation
Increased data protection and data security requirements
under the new EU Data Protection Regulation
13 June 2017
Dr. Lothar Ende
Dr. Lutz M. Keppeler
DVFA Life Science Conference 2017
• Heuking Kühn Lüer Wojtek •
Overview on data flows – simple case of a consumer device
13.06.2017 DVFA Life Science Conference 2017 2
Icon made by Freepik from www.flaticon.com
Wearables
Smartphone/App of
a user (medical
device?)
Provider of Operating
System/Smartphone
Cloud
Cloud Provider
ABC Ltd.
XYZ Inc.
Health
insurance
Hospital
• Heuking Kühn Lüer Wojtek •
Overview on data flows – simple case of a professional medical device
13.06.2017 DVFA Life Science Conference 2017 3
Icons made by Freepik from www.flaticon.com
Cloud Provider? Own Servers?
Health
insurance
External
Physician
Provider of Medical Device?
• Heuking Kühn Lüer Wojtek •
General Requirements under the GDPR
13.06.2017 DVFA Life Science Conference 2017 4
 Duty to examine the lawfulness of processing of personal data according to Articles 6 and 9
GDPR (Every act of data processing must be based on a Section which allows it)
 Compliance with the provisions for declarations of consent according to Articles 7 and 8
GDPR
 Transparent information of customers on the data processing (with respect to customers and
employees) according to Articles 13,14 GDPR
 Duty to delete data, the storage of which is no longer admissible (Art. 17 GDPR)
 Duty to make data provided by customers/employees available– in a conventional format – to
the customer/employee upon request (right to data portability) according to Art. 20 GDPR
• Heuking Kühn Lüer Wojtek •
General Requirements under the GDPR
13.06.2017 DVFA Life Science Conference 2017 5
 Compliance with the provisions on data protection by design and data protection by default
Art. 25 GDPR
 Obligation regarding data protection measures according to the state of the art (Art. 32 GDPR
- “data security by design”)
 Reports of data outflows after an IT security incident according to Art. 33 GDPR
 Compliance with the provisions in the case of the outsourcing of a data processing to a service
provider and other processors according to Art. 28 GDPR, including the provisions on the
transmission of data outside the EU or to subsidiary/sister companies)
• Heuking Kühn Lüer Wojtek •
Special rules on health-related data
13.06.2017 DVFA Life Science Conference 2017 6
 Special acts are applicable, particularly for health-related data:
 Law on medical products (Medizinproduktegesetz – Sec. 2 para. 4)
 Art. 9 paras. 1, 2 (a) GDPR (specific higher requirements for declarations of consent on
health-related data)
 Special requirements on personal data of clinical studies (Sec. 40 para. (1) No. 3 c)
German Drug Law - Arzneimittelgesetz)
 Special data protection requirements in the public healthcare sector (Social Code -
Sozialgesetzbuch V and X)
 Wide interpretation of the term “health-related data”
 Disclosure of health-related data by physician or by dentist, veterinarian, pharmacist is
considered as crime (imprisonment not exceeding one year or a fine) (Sec. 203 German
Criminal Code - Strafgesetzbuch)
• Heuking Kühn Lüer Wojtek •
New dimension of administrative fines
13.06.2017 DVFA Life Science Conference 2017 7
 Currently only a maximum fine of EUR 300,000 can be imposed
 Fines in the amount of up to EUR 10/20 million or 2/4% of the worldwide annual turnover
 Adequate to threaten international IT-Corporations / Dangerous for medium size companies
 Software/Medical devices are often not designed to comply with data protection requirements
• Heuking Kühn Lüer Wojtek •
Basic concepts of data protection law according to the GDPR
13.06.2017 DVFA Life Science Conference 2017 8
 The definition of „Personal data“ is defined extremely broad
 even dynamic IP-addresses must be considered as personal data
 Definition of „data processing“ is extremely broad
 Each controller must for each step of data processing comply with all before mentioned
requirements
 Joint controllership is possible (necessity to define who fulfils which requirement)
• Heuking Kühn Lüer Wojtek •
Compliance Obligation
13.06.2017 DVFA Life Science Conference 2017 9
 (…) the controller shall implement appropriate technical and organisational measures to
ensure and to be able to demonstrate that processing is performed in accordance with this
Regulation. Those measures shall be reviewed and updated where necessary (Art. 24 GDPR)
 Each controller and, where applicable, the controller's representative, shall maintain a record
of processing activities under its responsibility (Art. 30 GDPR)
 Where a type of processing (…) likely to result in a high risk (…) the controller shall, prior
to the processing, carry out an assessment of the impact of the envisaged processing
operations on the protection of personal data (Art. 35 GDPR)
= High documentation obligations and, as a result, a reversal of the burden of proof
• Heuking Kühn Lüer Wojtek •
IT-Security
 … the controller and the processor shall implement appropriate technical and organizational
measures to ensure a level of security appropriate to the risk (Art. 32 GDPR – data
security by design)
 Medical devices will have to be designed in a way that allow the processor to establish and
maintain necessary IT-security level  if not – defect, product liability
 What is appropriate?
 (…) taking into account the state of the art, the costs of implementation and the nature,
scope, context and purposes of processing (…)
 Not defined by case law
− Recommendation: Usage of recognized standards, such as ISO 2700x; BSI-
Grundschutz-Kataloge; „Standard-Datenschutz-Model („SDM“)
− Usually three steps: Risk analysis; Choice of adequate measures; Implementation
 Conclusion: Be pragmatic but document and explain why
13.06.2017 DVFA Life Science Conference 2017 10
• Heuking Kühn Lüer Wojtek •
Obligations to notify data breach
 GDRP: In the case of an IT security incident, an obligation to "promptly" notify the responsible
data protection authority (Art. 33 GDPR) and a message towards each affected data subject
(Art. 34 GDPR) is required
 German IT-Security Law: Notification to the Federal Office for Information Security; only
applicable on „provider of critical infrastructure” (like cloud service provider; hospitals)
 Parallel to this, ad-hoc publicity for listed companies
 Consequence: definition of the reporting process,
 Verification of the necessity to report
 Coordination of various departments (including public relations) and various undertakings
13.06.2017 DVFA Life Science Conference 2017 11
• Heuking Kühn Lüer Wojtek •
Berlin
Kurfürstendamm 32
10719 Berlin/Germany
T +49 30 88 00 97-0
F +49 30 88 00 97-99
Chemnitz
Weststrasse 16
09112 Chemnitz/Germany
T +49 371 38 203-0
F +49 371 38 203-100
Düsseldorf
Georg-Glock-Straße 4
40474 Düsseldorf/Germany
T +49 211 600 55-00
F +49 211 600 55-050
Frankfurt
Goetheplatz 5-7
60313 Frankfurt a. M./Germany
T +49 69 975 61-0
F +49 69 975 61-200
Hamburg
Neuer Wall 63
20354 Hamburg/Germany
T +49 40 35 52 80-0
F +49 40 35 52 80-80
Cologne
Magnusstrasse 13
50672 Cologne/Germany
T +49 221 20 52-0
F +49 221 20 52-1
Munich
Prinzregentenstrasse 48
80538 Munich/Germany
T +49 89 540 31-0
F +49 89 540 31-540
Stuttgart
Augustenstrasse 1
70178 Stuttgart/Germany
T +49 711 22 04 579-0
F +49 711 22 04 579-44
Brussels
Rue Froissart 95
1040 Brussels/Belgium
T +32 2 646 20-00
F +32 2 646 20-40
Zurich
Bahnhofstrasse 3
8001 Zurich/Switzerland
T +41 44 200 71-00
F +41 44 200 71-01
www.heuking.de
13.06.2017 DVFA Life Science Conference 2017 12
Thank you very much for your attention!
1
DIGITAL HEALTH TRENDS - WHAT ARE THE OPPORTINITIES FOR VENTURE CAPITAL
June 2017
The material set out in this draft document is confidential and may not be discussed with a third party nor passed to any third party except with the authorisation of Creathor Venture. Each person that receives a copy by acceptance
thereof represents and agrees that it will not reproduce, distribute or provide it to any other party. Creathor makes no representations or warranties with regard to the documents’ accuracy, completeness, non‐infringement or
suitability for a particular purpose.
2Private and Confidential
AGENDA
Creathor Venture Profile
Trends in Digital Health
Areas of Interest for Venture Capital
3Private and Confidential
AGENDA
Creathor Venture Profile
Trends in Digital Health
Areas of Interest for Venture Capital
4Private and Confidential
Earlystageventurecapitalfund
Zurich
BadHomburg
Stockholm
30%LifeScience
70%Technology
€220mAuM
5Private and Confidential
OUR TEAM WITH PROVEN TRACK RECORD
TEAM OVERVIEW
PlatformServices
Cédric Köhler
Team Support (DE)
Angela Will-Jamin
Finance Manager
Adrian Giessler
Team Support (DE)
Ute Molders
Christian Weniger
Alex Stöckl
Daniel Karsberg
Dr. Christian Weiss
Marianne Uddman
Christian Leikert
ManagingPartners
InvestmentTeam
SupportTeam
Thomas Dreiling
PR & Com-
munications
Marketing
Swetlana Gross
Karlheinz SchmeligDr. Gert Köhler
Atanas Mukov
Kathrin Leonhard
Team Support (CH)
Business
Intelligence
Fabian Degenhardt
6Private and Confidential
30+yearsventurecapitalinvesting
1984 2016
Sold to „Cheetah
Mobile“ ­ #3 top
app publisher
after Facebook
and Google
2015
Sold NASH
program to
„Gilead
Sciences“
$1B+
valuation
$1B+
valuation
$1B+
valuation
$1B+
valuation
$1B+
valuation
$1B+
valuation
$1B+
valuation
200+ investments
20 IPOs
1/3 own investment of the managing partners in the fund
7th fund generation
7Private and Confidential
INVESTMENT FOCUS
Technology
HR
Finance / Insurance
Travel
and Mobility
Property and
Real-Estate
NEXTGEN
SOFTWARE
Internet
of
Things
Sharing
Economy
Personalized
Medicine
ArtificialIntelligence
(incl. Big Data, Cloud, and
autonomus systems)
Medtech
GROWINGAREA OF TECH-
ENABLEDLIFE-SCIENCES
Tools
Diagnostics
8Private and Confidential
INVEStment FOCUS
Technology
HR
Finance / Insurance
Travel
and Mobility
Property and
Real-Estate
NEXTGEN
SOFTWARE
Internet
of
Things
Sharing
Economy
Personalized
Medicine
ArtificialIntelligence
(incl. Big Data, Cloud, and
autonomus systems)
Medtech
GROWINGAREA OF TECH-
ENABLEDLIFE-SCIENCES
Tools
Diagnostics
9Private and Confidential
Creathor Venture Profile
Trends in Digital Health
Areas of Interest for Venture Capital
10Private and Confidential
Wearables and
biosensing
Self Tracking
Analytics and Big
data
Smart Home
Care Coordination Telemedicine
TRENDS IN Digital Health
11Private and Confidential
TRENDS IN Digital Health: Plunging costs of IOT Sensors
12Private and Confidential
Source: https://www.genome.gov/sequencingcostsdata/
TRENDS IN Digital Health: Plunging costs OF dNA Sequencing
13Private and Confidential
Source: http://www.startuphealth.com/
TRENDS IN Digital Health: VENTURE CAPITAL INVESTMENTS
14Private and Confidential
The GERMAN Healthcare System (EUR250BN)
80.2 Million Inhabitants
(90% statutatory health
insurance, 10% private
insurance)
2.000 hospitals
200.000 practitioners
120 health insurance
companies
20.000 pharmacies
26.000 nursing homes,
residential care homes etc.
1.150 rehab centers/clinics
Administration through 200 non-interoperative IT-Systems
15Private and Confidential
The GERMAN Healthcare System
80.2 Million Inhabitants
(90% statutatory health
insurance, 10% private
insurance)
2.000 hospitals
200.000 practitioners
120 health insurance
companies
20.000 pharmacies
26.000 nursing homes,
residential care homes etc.
1.150 rehab centers/clinics
16Private and Confidential
Governance of the german healthcare system
Government
Gesundheitsministerium (Exekutive) Bundestag (Legislative)
delegation & decision making
Self - administration
2.000 hospitals 200.000 practitioners
120 health insurance
companies
20.000 pharmacies
26.000 nursing homes,
residential care homes etc.
1.150 rehab centers/clinics
17Private and Confidential
18Private and Confidential
History and future of digital health law in germany
2004: GKV-Modernisierungsgesetz
…
2015: E-Health Gesetz passed
2018: Roll-Out
1. IT – Infrastructure (gematik) finalized
2. Patient basic data management
3. Emergency Case data
4. E-Medication Plan
5. Telemedicine approaches (e-consultation, e x-ray interpretation)
6. Electronic Health record
19Private and Confidential
Creathor Venture Profile
Trends in Digital Health
Areas of Interest for Venture Capital
AGENDA
20
Hypothesis-market
pharma & medtech
health insurers, single­payer health care systems
tech giants (Google, Apple, IBM, Amazon, etc.)
try to find innovative solutions for the needs of
21
Hypothesis-needs
I. Ability to deliver more personalized patient care
II. Engage more fully with physicians and patients
III. Advanced analytics to increase pipeline and commercial value
22
Hypothesis-needs
Sensors and digital services for tailored, 24/7 treatment
E.g. mobile app for
managing type 2 diabetes,
smartphone­based
electrocardiogram, etc.
I. Ability to deliver more personalized patient care
23
Hypothesis-needs
Omnichannel conversations with physicians and
patients
Anytime­anywhere virtual care – portals, apps,
online patient communities
I. Ability to deliver more personalized patient care
II. Engage more fully with physicians and patients
24
Hypothesis-needs
I. Ability to deliver more personalized patient care
II. Engage more fully with physicians and patients
III. Advanced analytics to increase pipeline and commercial value
25
III. Advanced analytics to increase pipeline and commercial value
Hypothesis-needs
In R&D ­ digital discovery
and testing of molecules
with advanced modeling
and simulation techniques
“in silico screening”
In clinical development
speed up recruitment (via
social networks)
Patient monitoring (Sensors
& mobile apps)
Electronic data capture &
storage
In Marketing and Sales ­
advanced analytics to
understand prescribing
behavior and potential
patient profiles, enabling
more precise targeting
26Private and Confidential
Company Name Short Profile Creathor’s Role
Mobile testing Co‐lead
Developer of the world’s smartest connected bike system Co‐lead
Multi‐modal travel booking platform Investor
Meta‐search and booking platform for rental cars Co‐lead
Mobile job marketplace Co‐lead
Mobile corporate e‐health solution and platform Investor
Indoor navigation solution Investor
Digital insurance manager Investor
International B2B online sales and marketing tool Co‐lead
Ai‐enhanced marketplace for expert translations Co‐lead
Mobile app (brain training) Co‐lead
Market place for local crowd‐sourced service ecosystem Investor
Machine‐to‐machine communication for industrial applications Co‐lead
Mobile shopping and payment platform Lead
Mobile advertising Lead
Online referral marketing software & services Lead
Video marketing platform Lead
Web based sales support system Lead
Hotel booking solution Lead
Heyjobs
Lead investor or CO-Lead investor in majority of investments
Active Portfolio - Technology
27Private and Confidential
Company Name Short Profile Creathor’s Role
Innovative drug delivery platform with a focus on controlled‐release
formulations
Lead
High throughput multiplex protein/DNA analysis for both basic and clinical
research
Co‐lead
Chemical proteomics technology that permits the analysis of small molecule
interactions within protein mixtures in a targeted and directed manner
Lead
Recombinant proteins previously out of reach & scalable viral vectors Co‐lead
The Prostatype® Test System – a new gene test for prostate cancer patients Co‐lead
Proprietary cryotherapy system for use in the treatment of coronary artery
disease that causes heart attacks
Co‐Lead
Dedicated products and services for membrane protein applications that
facilitate analysis and drug development
Lead
Secure, smart and simple healthcare communication for doctors, patients and
medical professionals
Investor
Drug discovery and development company focused on small‐molecule drug
discovery with a special emphasis on the target class of nuclear receptors
Co‐lead
CE marked lacrimal stent for the treatment of Chronic Rhinosinusitis (CRS) and
Epiphora
Investor
Viral vector technologies from gene therapy and vaccination development to
customization of cell modelling tools
Lead
Significant ownership percentage and board positions in majority of investments
Active Portfolio - Life Sciences
Sample to Insight
Next-generation sequencing and big data
Jason T. Gammack
Vice President; Marketing & Product Management
Head of Global Marketing & Strategic Portfolio Management
DVFA Conference, June 2017 1
Sample to Insight
Disclaimer
2
Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact
are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section
21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying
assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and
projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and
competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and
dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our
products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic
partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general
economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products;
technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and
producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor
products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer
to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no
obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the
extent required by law.
Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally
accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted
operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes
should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes
certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or
affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of
Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in
the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high
variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of
these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the
actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.
GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis,
prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of
variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional
association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a
classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by
physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable
international, national and local clinical laboratory regulations and other accreditation requirements.
DVFA Conference, June 2017
Sample to Insight
DVFA Conference, June 2017
SCIENTIFIC BREAKTHROUGHS
WE ARE EXPERIENCING A NEW AGE OF
Dramatic breakthroughs in molecular biology enable big data creation
We are creating more biological data
every 6 months than in all of prior history
1) Source: Cisco Systems, GenBank and Alliance Bernstein
3
Sample to Insight
DVFA Conference, June 2017 4
Data phase Astronomy Twitter YouTube Genomics
Acquisition 25 zetta-bytes/year 0.5-15 billion tweets/year 500-900 million
hours/year
1 zetta-bases/year
Storage 1 EB/year 1-17 PB/year 1-2 EB/year 2-40 EB/year
Analysis In situ data reduction Topic and sentiment
mining
Limited requirements Heterogenous data and
analysis
Real-time processing Metadata analysis Variant calling, -2 trillion
central processing unit
(CPU) hours
Massive volumes All-pairs genome
alignments, - 10,000
trillion CPU hours
Distribution Dedicated lines from
antennae to server
Small units of
distribution
Major component of
modern user’s
bandwidth (10MB/s)
Many small (10 MB/s)
and fewer massive (10
TB/s) data movement
Genomics is truly a big (BIG!) data environment
The four domains of big data in 2015(1)
1) Source: Stephens ZD, Lee SY, Faghri F, Campbell RH, Zhai C, et al. (2015) Big Data: Astronomical or Genomical?
Sample to Insight
DVFA Conference, June 2017 5
Rapidly evolving sequencing techniques initiated a new era of genomic insights
1953 1977
Sanger develops
1st DNA sequencing
technique
1st personal
human genome
is sequenced
1st bacterium
genome is
sequenced
1995 2002
1st mammal
genome
is sequenced
2009
First NGS
tumor genome
analysis
1st Illumina
human genome
is sequenced
2008
1st 454
human genome
is sequenced
Next-generation DNA
sequencing technology
is introduced
2007
Sample to Insight
DVFA Conference, June 2017 6
The growth of DNA sequencing
1) Source: Stephens ZD, Lee SY, Faghri F, Campbell RH, Zhai C, et al. (2015), Big Data: Astronomical or Genomical?
The power of genomics is fueled by big data
Sample to Insight
DVFA Conference, June 2017 7
How can we extract
insights
from increasingly large
and complex data?
Sample to Insight
8DVFA Conference, June 2017
How can we
share data
And find new models
of collaboration?
Sample to Insight
9DVFA Conference, June 2017
How can we
scale
interpretation
despite skill and
time requirements?
Sample to Insight
10DVFA Conference, June 2017
How can we use
Big Data
to make better
treatment decisions?
Sample to Insight
DVFA Conference, June 2017 11
PharmaAcademia Molecular Diagnostics
Applied
Testing
QIAGEN well-positioned across all segments of the NGS market
GeneReader NGS System
Universal NGS
 Single-cell genomics
 Gene expression
 Targeted resequencing
 Whole exome
 Whole genome
 Clinical research
 Translational medicine
 Oncology
 Hereditary diseases
 Infectious diseases
Interpretation
Nucleic acid
collection &
extraction
Target
enrichment
Library
preparation
Next-
generation
sequencing
Data
analysis
Universal NGS:
QIAseq portfolio
Universal NGS:
CLC / Ingenuity / QCI
GeneReader NGS System
Sample to Insight
12
QIAGEN Bioinformatics driving innovations from R&D to the clinic
Research &
Discovery
Clinical
Development
Microbial Pro Suite
IPA
Genomics Workbench
Genomics Server
Microbial RNA-Seq
Microbial Epigenetics
ExploreRNA
HVSS
IVA
Biomedical Workbench
HVSS
HGMD
QCI-Analyze
QCI-Interpret
Knowledge base
curation
Services
Algorithm development
DVFA Conference, June 2017
Sample to Insight
13
Delivering faster and better insights across full range of customer needs
DVFA Conference, June 2017
Acquisition of OmicSoftEnhancing QIAGEN Bioinformatics portfolio
 Leader in enterprise solutions for large-scale omics
data management
 Curation, standardization and comparative analysis
of large-scale NGS and omics datasets
 Adds infrastructure solutions for
 Own data mining
 Data sharing
 Adds highly curated data set
Highly
curated
literature
Data
sharingHighly
curated
content
Own data
mining
NEW NEW
QIAGEN now covers the full range of
data interpretation and sharing needs
Sample to Insight
14
Actionable
insights
Expertise
and service
First complete
NGS workflow
Flexibility to
fit needs
Reliable resultsEase of use
Unique automation Data interpretation
QIAcube® GeneRead QIAcube® GeneReaderTM Bioinformatics portfolio
Predictable
costs
The world’s first complete Sample to Insight NGS solution for actionable results
1 3 4 52
DVFA Conference, June 2017
Sample to Insight
DVFA Conference, June 2017 15
Setting new standards with QIAGEN Clinical Insight in clinical decision making
QCI workflow
 Full integration for fast and seamless data analysis
 Easy-to-use analysis tool for clinical researchers
 Efficient pre-designed data analysis optimized to panel content
 Operational scale: workflow and decision-assisted automation
 Aligned with regulatory and reimbursement requirements
 Integration of HGMD (Human Gene Mutation Database)
Identify
variants
Analyze Review Report
QIAGEN Clinical Insight is an integral part of GeneReader NGS workflow
Sample to Insight
0
10
20
30
40
50
60
70
80
90
Manual QCI Interpret
Hours
DVFA Conference, June 2017 16
QIAGEN Clinical Insight: Helping to achieve faster and more accurate insights
75%
time reduction
InterpretationLiterature curation
Case study: the power of QIAGEN Bioinformatics
33% reduction in
variants of unknown
significance
0
10
20
30
40
50
60
70
80
90
Pathogenic Likely
Pathogenic
VUS Likely
Benign
Benign
Variants
With QIAGENWithout QIAGEN
Case study: Cardiology variant classification(1)Case study: QCI interpretation time benefits
(1) Data from QCI Interpret with and without QIAGEN curated primary literature.
Data is represented as the difference between variant classifications with QIAGEN content minus variant classifications without QIAGEN content.
Sample to Insight
Screening Diagnosis Prognosis Treatment Monitoring Surveillance
DVFA Conference, June 2017 17
Molecular methods support decision making along the patient journey
Sample to Insight
DVFA Conference, June 2017 18
QCI Interpret: Streamlining interpretation and reporting of NGS data
Sample to Insight
DVFA Conference, June 2017 19
QCI Interpret: Streamlining interpretation and reporting of NGS data
Sample to Insight
Solving challenges of complex genomic data
Market leader in analysis, interpretation and content
Portfolio with strong commercial traction
20
Summary
DVFA Conference, June 2017
Clemens Suter-Crazzolara, PhD.
May 2017
The Health Revolution – Better Outcomes with
Smart Data
2© 2017 SAP SE or an SAP affiliate company. All rights reserved.
Legal Disclaimer
The information in this document is confidential and proprietary to SAP and may not be disclosed without the
permission of SAP. This document is not subject to your license agreement or any other service or subscription
agreement with SAP. SAP has no obligation to pursue any course of business outlined in this document or any
related presentation, or to develop or release any functionality mentioned therein. This document, or any
related presentation and SAP’s strategy and possible future developments, products and or platforms
directions and functionality are all subject to change and may be changed by SAP at any time for any reason
without notice. The information on this document is not a commitment, promise or legal obligation to deliver
any material, code or functionality. This document is provided without a warranty of any kind, either express or
implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose,
or non-infringement. This document is for informational purposes and may not be incorporated into a contract.
SAP assumes no responsibility for errors or omissions in this document, except if such damages were caused
by SAP intentionally or grossly negligent.
All forward-looking statements are subject to various risks and uncertainties that could cause actual results to
differ materially from expectations.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of their dates, and they should not be relied upon in making purchasing decisions.
3© 2017 SAP SE or an SAP affiliate company. All rights reserved.
Global Trends Impacting Patients and the Industry at Large
Escalating Costs Increasing Demand
‘Sleeping Giant’:
Patients as Consumers
4© 2017 SAP SE or an SAP affiliate company. All rights reserved.
Value-Based
Care and Patient
Outcomes
Response to Market Forces Drives Transformational Change
Escalating
Costs
Increasing
Demand
Patients as
Consumers
Legislation / Payment Reform
MACRA
APM MIPS
MACRA = Medicare Access
and CHIP Reauthorization Act
APM = Advanced Alternative
Payment Models
MIPS = Merit-based Incentive
Payment System
Population Health, Disease
Management and Precision Medicine
Patient Engagement
5© 2017 SAP SE or an SAP affiliate company. All rights reserved.
The Opportunity: Combining Cross Ecosystem Data
in Innovative New Ways to Reveal Breakthrough Findings
Patient timeline
PubMed Biomedical
Article Database
Clinical Trials
Currently more than 30,000
recruiting on ClinicalTrials.gov
Cancer Patient Records
at the National Center for Tumor
(NCT) Diseases in Heidelberg
Clinical information
management systems
Often more than 50 GB
Human Proteome
data points (2.4 GB) per sample;
7.6 TB raw proteome data on
ProteomicsDB.org
Prescription Data
records from 10,000 doctors and
10 million patients (100 GB)
Human Genome and
Biological Data
from a single genome; >15 PB in
databases of leading institutes
Medical Imaging Data
1 second scan of a single organ
Gain Longitude Views of
Patient Healthcare History
Gain Comprehensive Views of Cross-Population Health and Industry Insights
160M 1.5B 50GB
160K >25M 10GB
800MB 30K
Diagnosis
Tumor Stage
Pathology Report
Tissue Sample
Genomic Markers
Radiotherapy
6© 2017 SAP SE or an SAP affiliate company. All rights reserved.
Framework for Live Business from SAP
7© 2017 SAP SE or an SAP affiliate company. All rights reserved.
S4 PA
S4 ERP
Patient
Relationship
Management
SAP Expertly Applies Technology within Healthcare Business Contexts to
Power Innovation
Research and Clinical Delivery
How do I assemble and
manage my care team based
on the needs of my patient? How do I design and run my
supply chain based on the
needs of my patients?
S4 ERP
Ariba
Fieldglass
SucessFactors
S4 PM
SAP Health
Leonardo Co-Innovation
Patient
Revenue Optimization
• How do I maximize my revenue
and collections from patient (billing)
• How to acquire new patients and
retain existing ones (marketing)?
Research & Clinical
Delivery
How do I enable my
clinicians to deliver
evidence-based care
Supply Chain/
Ops
Workforce
Engagement
8© 2017 SAP SE or an SAP affiliate company. All rights reserved.
Specialized
Hospitals
Rehabilitation
Community
Practice
Pharma Research
Payer
Medical
Devices
LabsProviders
SAP Health Enables Actionable Insights by Leveraging the Healthcare
Ecosystem
Patient
Connected
Integrate evolving data sets
across the healthcare
continuum
Real-time
Provide up-to-the-moment
insights for improved decision
making and greater patient and
population health insights
Actionable
Advanced analytics and
queries to spot trends, run
scenarios, set new standards
for treatment and delivery
9© 2017 SAP SE or an SAP affiliate company. All rights reserved.
SAP Health Drives Innovation as the Catalyst for Healthcare Transformation
SAP Applications
• Patient Engagement
• Patient Management
• Clinical Research
• Clinical Quality
.
Partner Applications
Facilitates Healthcare Network
collaboration through integrated insights
and application services that support
coordinated patient-centric, health and
wellness scenarios
SAP Federated Data and Analytics
Connecting data silos, providing real time
insights, and supported by SAP HANA in-
memory computing for improved decision-
making, hypothesis-building and testing
Accelerated Innovation with broad application portfolio, connected medical devices, automation and machine learning
Integrated User Interface
SAP Health Platform
SAP HANA Platform
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017
Dvfa life-science-conference-proceedings-2017

More Related Content

What's hot

The future of healthcare: when mobile disappears
The future of healthcare: when mobile disappearsThe future of healthcare: when mobile disappears
The future of healthcare: when mobile disappears
Matteo Penzo
 
Smart Health Centers-Navigator Training
Smart Health Centers-Navigator TrainingSmart Health Centers-Navigator Training
Smart Health Centers-Navigator Training
Smart Chicago Collaborative
 
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell GroupCyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
Julien de Salaberry
 
Hcit is different
Hcit is differentHcit is different
Hcit is different
Pankaj Gupta
 
Speech recognition and clinical knowledge systems
Speech recognition and clinical knowledge systemsSpeech recognition and clinical knowledge systems
Speech recognition and clinical knowledge systems
Klaus Stanglmayr
 
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
Yoon Sup Choi
 
디지털 신약, 누구도 가보지 않은 길
디지털 신약, 누구도 가보지 않은 길디지털 신약, 누구도 가보지 않은 길
디지털 신약, 누구도 가보지 않은 길
Yoon Sup Choi
 
Final EABF - Healthcare Financing - 15022022
Final EABF - Healthcare Financing - 15022022Final EABF - Healthcare Financing - 15022022
Final EABF - Healthcare Financing - 15022022
MEDx eHealthCenter
 
ISHSH 2013_On offline total service of community-based healthcare smart home_...
ISHSH 2013_On offline total service of community-based healthcare smart home_...ISHSH 2013_On offline total service of community-based healthcare smart home_...
ISHSH 2013_On offline total service of community-based healthcare smart home_...
Jeongeun Kim
 
The Propell Group - ESSEC Business School - Digital Health Innovation
The Propell Group - ESSEC Business School - Digital Health InnovationThe Propell Group - ESSEC Business School - Digital Health Innovation
The Propell Group - ESSEC Business School - Digital Health Innovation
Julien de Salaberry
 
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
Yoon Sup Choi
 
Force multiplier framework
Force multiplier frameworkForce multiplier framework
Force multiplier framework
Pankaj Gupta
 
디지털 치료제, 또 하나의 신약
디지털 치료제, 또 하나의 신약디지털 치료제, 또 하나의 신약
디지털 치료제, 또 하나의 신약
Yoon Sup Choi
 
Rock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_HealthRock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_Health
Rock Health
 
의료의 미래, 디지털 헬스케어
의료의 미래, 디지털 헬스케어의료의 미래, 디지털 헬스케어
의료의 미래, 디지털 헬스케어
Yoon Sup Choi
 
The Future of Healthcare | Smart Health coLAB
The Future of Healthcare | Smart Health coLABThe Future of Healthcare | Smart Health coLAB
The Future of Healthcare | Smart Health coLAB
Julien de Salaberry
 
8 Management tools that improve Patient safety
8 Management tools that improve Patient safety8 Management tools that improve Patient safety
8 Management tools that improve Patient safety
Imperago Ltd
 
Future of health Care
Future of health CareFuture of health Care
Future of health Care
James Canton
 
Smart health care
Smart health careSmart health care
Smart health care
Anish Das
 
New Normal, New Future - Free Download E book
New Normal, New Future - Free Download E bookNew Normal, New Future - Free Download E book
New Normal, New Future - Free Download E book
kevin brown
 

What's hot (20)

The future of healthcare: when mobile disappears
The future of healthcare: when mobile disappearsThe future of healthcare: when mobile disappears
The future of healthcare: when mobile disappears
 
Smart Health Centers-Navigator Training
Smart Health Centers-Navigator TrainingSmart Health Centers-Navigator Training
Smart Health Centers-Navigator Training
 
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell GroupCyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group
 
Hcit is different
Hcit is differentHcit is different
Hcit is different
 
Speech recognition and clinical knowledge systems
Speech recognition and clinical knowledge systemsSpeech recognition and clinical knowledge systems
Speech recognition and clinical knowledge systems
 
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
의료의 미래, 디지털 헬스케어: 제약산업을 중심으로
 
디지털 신약, 누구도 가보지 않은 길
디지털 신약, 누구도 가보지 않은 길디지털 신약, 누구도 가보지 않은 길
디지털 신약, 누구도 가보지 않은 길
 
Final EABF - Healthcare Financing - 15022022
Final EABF - Healthcare Financing - 15022022Final EABF - Healthcare Financing - 15022022
Final EABF - Healthcare Financing - 15022022
 
ISHSH 2013_On offline total service of community-based healthcare smart home_...
ISHSH 2013_On offline total service of community-based healthcare smart home_...ISHSH 2013_On offline total service of community-based healthcare smart home_...
ISHSH 2013_On offline total service of community-based healthcare smart home_...
 
The Propell Group - ESSEC Business School - Digital Health Innovation
The Propell Group - ESSEC Business School - Digital Health InnovationThe Propell Group - ESSEC Business School - Digital Health Innovation
The Propell Group - ESSEC Business School - Digital Health Innovation
 
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
의료의 미래, 디지털 헬스케어 + 의료 시장의 특성
 
Force multiplier framework
Force multiplier frameworkForce multiplier framework
Force multiplier framework
 
디지털 치료제, 또 하나의 신약
디지털 치료제, 또 하나의 신약디지털 치료제, 또 하나의 신약
디지털 치료제, 또 하나의 신약
 
Rock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_HealthRock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_Health
 
의료의 미래, 디지털 헬스케어
의료의 미래, 디지털 헬스케어의료의 미래, 디지털 헬스케어
의료의 미래, 디지털 헬스케어
 
The Future of Healthcare | Smart Health coLAB
The Future of Healthcare | Smart Health coLABThe Future of Healthcare | Smart Health coLAB
The Future of Healthcare | Smart Health coLAB
 
8 Management tools that improve Patient safety
8 Management tools that improve Patient safety8 Management tools that improve Patient safety
8 Management tools that improve Patient safety
 
Future of health Care
Future of health CareFuture of health Care
Future of health Care
 
Smart health care
Smart health careSmart health care
Smart health care
 
New Normal, New Future - Free Download E book
New Normal, New Future - Free Download E bookNew Normal, New Future - Free Download E book
New Normal, New Future - Free Download E book
 

Similar to Dvfa life-science-conference-proceedings-2017

Dvfa life-science-flyer-2017 (1)
Dvfa life-science-flyer-2017 (1)Dvfa life-science-flyer-2017 (1)
Dvfa life-science-flyer-2017 (1)
http://www.universidadazteca.net/study_offers
 
Europe's Top 5 Effective Leaders in Healthcare Edition.pdf
Europe's Top 5 Effective Leaders in Healthcare Edition.pdfEurope's Top 5 Effective Leaders in Healthcare Edition.pdf
Europe's Top 5 Effective Leaders in Healthcare Edition.pdf
insightscare
 
Europe's Top 5 Effective Leaders in Healthcare.pdf
Europe's Top 5 Effective Leaders in Healthcare.pdfEurope's Top 5 Effective Leaders in Healthcare.pdf
Europe's Top 5 Effective Leaders in Healthcare.pdf
insightscare
 
Digital_Health_Zug_Event_04-04-2016
Digital_Health_Zug_Event_04-04-2016Digital_Health_Zug_Event_04-04-2016
Digital_Health_Zug_Event_04-04-2016
Michael Dillhyon
 
20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event
DayOne
 
10 most prominent telehealth solution providers in 2021
10 most prominent telehealth solution providers in 202110 most prominent telehealth solution providers in 2021
10 most prominent telehealth solution providers in 2021
insightscare
 
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare MagazineContinuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
kevin brown
 
Big Data and eHealth Event
Big Data and eHealth EventBig Data and eHealth Event
Big Data and eHealth Event
Shaun Braun
 
First announcement - BigData and eHealth
First announcement - BigData and eHealthFirst announcement - BigData and eHealth
First announcement - BigData and eHealth
@NWlongworth (Nick Longworth)
 
HealthPanel Concept pitchdeck
HealthPanel Concept pitchdeckHealthPanel Concept pitchdeck
HealthPanel Concept pitchdeck
smworth
 
Consumerism, Innovation and Best Practices to Thrive in the Future of Health
Consumerism, Innovation and Best Practices to Thrive in the Future of HealthConsumerism, Innovation and Best Practices to Thrive in the Future of Health
Consumerism, Innovation and Best Practices to Thrive in the Future of Health
Justin Barnes
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Tony Couch
 
Qrepublik MedID Presentation Product (NEW)_compressed.pdf
Qrepublik MedID Presentation Product (NEW)_compressed.pdfQrepublik MedID Presentation Product (NEW)_compressed.pdf
Qrepublik MedID Presentation Product (NEW)_compressed.pdf
QREPUBLIC, INC.
 
Patient-Centered Clinical Trials 2015
Patient-Centered Clinical Trials 2015Patient-Centered Clinical Trials 2015
Patient-Centered Clinical Trials 2015
Nassim Azzi, MBA
 
IMS Health Real-World Evidence Solutions at ISPOR November 2015
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMS Health Real-World Evidence Solutions at ISPOR November 2015
IMS Health Real-World Evidence Solutions at ISPOR November 2015
IMSHealthRWES
 
Future of Health Report - PSK
Future of Health Report - PSKFuture of Health Report - PSK
Future of Health Report - PSK
Josh Trent
 
The 10 eminent leaders in healthcare for 2020 compressed
The 10 eminent leaders in healthcare for 2020 compressedThe 10 eminent leaders in healthcare for 2020 compressed
The 10 eminent leaders in healthcare for 2020 compressed
insightscare
 
20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving
D3 Consutling
 
20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving
Ann Huygelier
 
Promise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health carePromise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health care
Δρ. Γιώργος K. Κασάπης
 

Similar to Dvfa life-science-conference-proceedings-2017 (20)

Dvfa life-science-flyer-2017 (1)
Dvfa life-science-flyer-2017 (1)Dvfa life-science-flyer-2017 (1)
Dvfa life-science-flyer-2017 (1)
 
Europe's Top 5 Effective Leaders in Healthcare Edition.pdf
Europe's Top 5 Effective Leaders in Healthcare Edition.pdfEurope's Top 5 Effective Leaders in Healthcare Edition.pdf
Europe's Top 5 Effective Leaders in Healthcare Edition.pdf
 
Europe's Top 5 Effective Leaders in Healthcare.pdf
Europe's Top 5 Effective Leaders in Healthcare.pdfEurope's Top 5 Effective Leaders in Healthcare.pdf
Europe's Top 5 Effective Leaders in Healthcare.pdf
 
Digital_Health_Zug_Event_04-04-2016
Digital_Health_Zug_Event_04-04-2016Digital_Health_Zug_Event_04-04-2016
Digital_Health_Zug_Event_04-04-2016
 
20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event
 
10 most prominent telehealth solution providers in 2021
10 most prominent telehealth solution providers in 202110 most prominent telehealth solution providers in 2021
10 most prominent telehealth solution providers in 2021
 
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare MagazineContinuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
Continuous Surveillance | Ahhm Healthcare Issue 47 - Asian Healthcare Magazine
 
Big Data and eHealth Event
Big Data and eHealth EventBig Data and eHealth Event
Big Data and eHealth Event
 
First announcement - BigData and eHealth
First announcement - BigData and eHealthFirst announcement - BigData and eHealth
First announcement - BigData and eHealth
 
HealthPanel Concept pitchdeck
HealthPanel Concept pitchdeckHealthPanel Concept pitchdeck
HealthPanel Concept pitchdeck
 
Consumerism, Innovation and Best Practices to Thrive in the Future of Health
Consumerism, Innovation and Best Practices to Thrive in the Future of HealthConsumerism, Innovation and Best Practices to Thrive in the Future of Health
Consumerism, Innovation and Best Practices to Thrive in the Future of Health
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 
Qrepublik MedID Presentation Product (NEW)_compressed.pdf
Qrepublik MedID Presentation Product (NEW)_compressed.pdfQrepublik MedID Presentation Product (NEW)_compressed.pdf
Qrepublik MedID Presentation Product (NEW)_compressed.pdf
 
Patient-Centered Clinical Trials 2015
Patient-Centered Clinical Trials 2015Patient-Centered Clinical Trials 2015
Patient-Centered Clinical Trials 2015
 
IMS Health Real-World Evidence Solutions at ISPOR November 2015
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMS Health Real-World Evidence Solutions at ISPOR November 2015
IMS Health Real-World Evidence Solutions at ISPOR November 2015
 
Future of Health Report - PSK
Future of Health Report - PSKFuture of Health Report - PSK
Future of Health Report - PSK
 
The 10 eminent leaders in healthcare for 2020 compressed
The 10 eminent leaders in healthcare for 2020 compressedThe 10 eminent leaders in healthcare for 2020 compressed
The 10 eminent leaders in healthcare for 2020 compressed
 
20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving
 
20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving20130226 impact van zorg 2 0 op onze samenleving
20130226 impact van zorg 2 0 op onze samenleving
 
Promise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health carePromise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health care
 

More from http://www.universidadazteca.net/study_offers

Life science conference dvfa1
Life science conference   dvfa1Life science conference   dvfa1
Life science conference dvfa1
http://www.universidadazteca.net/study_offers
 
Poster presentation rsm london
Poster presentation rsm londonPoster presentation rsm london
Poster presentation rsm london
http://www.universidadazteca.net/study_offers
 
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
http://www.universidadazteca.net/study_offers
 
Curriculum vitae 2016
Curriculum vitae 2016Curriculum vitae 2016
Syllabi MBA MSc / Dr. PhD
Syllabi MBA MSc / Dr. PhDSyllabi MBA MSc / Dr. PhD
MSc and Doctor of Philosophy inter-university programmesp health economics m ...
MSc and Doctor of Philosophy inter-university programmesp health economics m ...MSc and Doctor of Philosophy inter-university programmesp health economics m ...
MSc and Doctor of Philosophy inter-university programmesp health economics m ...
http://www.universidadazteca.net/study_offers
 
MSc and MBA inter-university programme
MSc and MBA inter-university programmeMSc and MBA inter-university programme
MSc and MBA inter-university programme
http://www.universidadazteca.net/study_offers
 
Patent regulation
Patent regulationPatent regulation
Gesundheitsökonomie Health Economics
Gesundheitsökonomie Health EconomicsGesundheitsökonomie Health Economics
Gesundheitsökonomie Health Economics
http://www.universidadazteca.net/study_offers
 
Gesundheitsökonomie Health Economics
Gesundheitsökonomie Health EconomicsGesundheitsökonomie Health Economics
Gesundheitsökonomie Health Economics
http://www.universidadazteca.net/study_offers
 
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
http://www.universidadazteca.net/study_offers
 
Research article
Research articleResearch article
Horizon 2020
 Horizon 2020  Horizon 2020
Pastoralpsychologie in der Gerontopsyhiatrie
Pastoralpsychologie in der GerontopsyhiatriePastoralpsychologie in der Gerontopsyhiatrie
Pastoralpsychologie in der Gerontopsyhiatrie
http://www.universidadazteca.net/study_offers
 
Mind-Body-Medicine und Information
Mind-Body-Medicine und InformationMind-Body-Medicine und Information
Mind-Body-Medicine und Information
http://www.universidadazteca.net/study_offers
 
Poster presentation Royal Society Of Medicine London
Poster presentation Royal Society Of Medicine LondonPoster presentation Royal Society Of Medicine London
Poster presentation Royal Society Of Medicine London
http://www.universidadazteca.net/study_offers
 

More from http://www.universidadazteca.net/study_offers (20)

Life science conference dvfa1
Life science conference   dvfa1Life science conference   dvfa1
Life science conference dvfa1
 
Poster presentation rsm london
Poster presentation rsm londonPoster presentation rsm london
Poster presentation rsm london
 
Imi mhealth-service web.pdf-extract
Imi mhealth-service web.pdf-extractImi mhealth-service web.pdf-extract
Imi mhealth-service web.pdf-extract
 
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
Deskriptiver regulationsbiologischer hintergrund der wirkung von body waves u...
 
Curriculum vitae 2016
Curriculum vitae 2016Curriculum vitae 2016
Curriculum vitae 2016
 
Ehrung Prof. Lingg ots 20150718_ots0008
Ehrung Prof. Lingg ots 20150718_ots0008Ehrung Prof. Lingg ots 20150718_ots0008
Ehrung Prof. Lingg ots 20150718_ots0008
 
Syllabi MBA MSc / Dr. PhD
Syllabi MBA MSc / Dr. PhDSyllabi MBA MSc / Dr. PhD
Syllabi MBA MSc / Dr. PhD
 
MSc and Doctor of Philosophy inter-university programmesp health economics m ...
MSc and Doctor of Philosophy inter-university programmesp health economics m ...MSc and Doctor of Philosophy inter-university programmesp health economics m ...
MSc and Doctor of Philosophy inter-university programmesp health economics m ...
 
MSc and MBA inter-university programme
MSc and MBA inter-university programmeMSc and MBA inter-university programme
MSc and MBA inter-university programme
 
Patent regulation
Patent regulationPatent regulation
Patent regulation
 
Gesundheitsökonomie Health Economics
Gesundheitsökonomie Health EconomicsGesundheitsökonomie Health Economics
Gesundheitsökonomie Health Economics
 
Gesundheitsökonomie Health Economics
Gesundheitsökonomie Health EconomicsGesundheitsökonomie Health Economics
Gesundheitsökonomie Health Economics
 
Gesundheitsökonomie Health Economics
Gesundheitsökonomie Health EconomicsGesundheitsökonomie Health Economics
Gesundheitsökonomie Health Economics
 
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
Treatment of Highland Frogs from the Two- Legged Stage with Homeopathically P...
 
Research article
Research articleResearch article
Research article
 
Horizon 2020
 Horizon 2020  Horizon 2020
Horizon 2020
 
Patent china
Patent chinaPatent china
Patent china
 
Pastoralpsychologie in der Gerontopsyhiatrie
Pastoralpsychologie in der GerontopsyhiatriePastoralpsychologie in der Gerontopsyhiatrie
Pastoralpsychologie in der Gerontopsyhiatrie
 
Mind-Body-Medicine und Information
Mind-Body-Medicine und InformationMind-Body-Medicine und Information
Mind-Body-Medicine und Information
 
Poster presentation Royal Society Of Medicine London
Poster presentation Royal Society Of Medicine LondonPoster presentation Royal Society Of Medicine London
Poster presentation Royal Society Of Medicine London
 

Recently uploaded

Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
kkirkland2
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
gharris9
 
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Dutch Power
 
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussionPro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
OECD Directorate for Financial and Enterprise Affairs
 
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussionPro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
OECD Directorate for Financial and Enterprise Affairs
 
2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
Frederic Leger
 
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussionArtificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
OECD Directorate for Financial and Enterprise Affairs
 
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
SkillCertProExams
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
amekonnen
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Rosie Wells
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
samililja
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
OECD Directorate for Financial and Enterprise Affairs
 
Gregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptxGregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptx
gharris9
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Dutch Power
 
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
OECD Directorate for Financial and Enterprise Affairs
 
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPointMẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
1990 Media
 
Carrer goals.pptx and their importance in real life
Carrer goals.pptx  and their importance in real lifeCarrer goals.pptx  and their importance in real life
Carrer goals.pptx and their importance in real life
artemacademy2
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij
 
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
gpww3sf4
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
Faculty of Medicine And Health Sciences
 

Recently uploaded (20)

Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
 
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
 
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussionPro-competitive Industrial Policy – OECD – June 2024 OECD discussion
Pro-competitive Industrial Policy – OECD – June 2024 OECD discussion
 
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussionPro-competitive Industrial Policy – LANE – June 2024 OECD discussion
Pro-competitive Industrial Policy – LANE – June 2024 OECD discussion
 
2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
 
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussionArtificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
Artificial Intelligence, Data and Competition – LIM – June 2024 OECD discussion
 
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
 
Gregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptxGregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptx
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
 
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
Artificial Intelligence, Data and Competition – ČORBA – June 2024 OECD discus...
 
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPointMẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
 
Carrer goals.pptx and their importance in real life
Carrer goals.pptx  and their importance in real lifeCarrer goals.pptx  and their importance in real life
Carrer goals.pptx and their importance in real life
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
 
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
原版制作贝德福特大学毕业证(bedfordhire毕业证)硕士文凭原版一模一样
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
 

Dvfa life-science-conference-proceedings-2017

  • 1. Society of Investment Professionals in Germany Digital Transformation in Healthcare 13 June 2017 DVFA Center, Frankfurt am Main 10th DVFA Life Science Conference Supported by Media Partner Schnee Research Plattform Life Sciences Networking Partner Conference Proceedings
  • 2. LIFE SCIENCE_ Disclaimer_ This brochure contains information from sources believed to be reliable but has not been verified or testified. The corporate data provided has been transmitted and converted elec- tronically. Therefore, the information cannot be guaranteed to be secure or error-free as the transmitted and converted information could be intercepted, corrupted, lost or incomplete. Thus, DVFA does not accept liability for any errors or omissions regarding the contents of this information. Financial data presented by the companies as reported by the corporates. The conference brochure is provided for information purposes and should not be construed as a solicitation or offer to buy or sell any securities or related financial instruments. Please note that the data given in this brochure may be rounded. Deviations may thus oc- cur, e.g. regarding percentage figures. The company information is provided by the respective companies. DVFA cannot assume any responsibility for the correctness and completeness of this information. Any copying, distribution or any action taken or omitted to be taken in reliance on it is pro- hibited and may be unlawful. © 2017 DVFA GmbH ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher and the co- pyright holder.
  • 3. The 10th DVFA Life Science Conference focused on the challenges and opportunities of Digital Transformation in Healthcare. With the explosive growth in health and biomedical data the digital transformation of the healthcare sector is gaining momentum. Participants got insights in Network medicine, Telematics Infrastructure, Electronic Health Records (EHR), Medical Apps & Cloud, EU data protection rules and discuss the future of digital medicine with industry experts. u Topics  Digital Transformation in Healthcare: Challenges & Opportunities  The Telematics Infrastructure: The coming eHealth Revolution in Germany  Connected Diabetes Management  Increased data protection and data security requirements under the new EU Data Protection Regulation  Panel Discussion – New Business Models Digital Health  Next Generation Sequencing & Big Data  The Health Revolution – Better Outcomes with Smart Data  Panel Discussion – Digital Health: A Capital Market Perspective  Digital Health – Startup-Slam u Speakers & Moderators  Dr. Christa Bähr, CEFA, CFA, Founder and Business Owner, CB HealthCare  Kai Brüning, CEFA, Fundsmanager, apoAsset Management GmbH  Eric Cohen, IR, Cellnovo Group  Dr. Lothar Ende, Partner, HEUKING KÜHN LÜER WOJTEK  Jason Gammack, Vice President Head of Marketing Life Sciences, QIAGEN N.V.  Dr. Lutz Martin Keppeler, Senior Associate, Certified Specialist Lawyer for Information Technology Law, HEUKING KÜHN LÜER WOJTEK  Prof. Dr. Dr. Gerhard Lingg PhD, Chairman, imi mHealth Solutions Ltd.  Dr. med. Markus Manns, Chairman DVFA Life Science Commission, Equities Fund Manager, Union Investment Privatfonds GmbH  Klaus May, Geschäftsführer, Genomatix  Dr. Martin Pöhlchen, Partner, Alira Health  Karlheinz Schmelig, Managing Partner, Creathor Venture  Carsten Schmitt, Investment Banking, Renell Bank  Dr. Julia Schüler, CBA, Investor Relations, SynapCon  Roman Schweiger, CFO, HUMANOO  Julian Shapley, CSO, Cellnovo Group  Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE  Dr. Klaus Suwelack, New Venture Lead Germany, Johnson & Johnson Innovation/Janssen  Christian B. Teig, CFO, CompuGroup Medical  Lesli Wagstaffe, CEO, imi mHealth Solutions Ltd. LIFE SCIENCE_ Conference 13 June 2017, 9 a.m.
  • 4. LIFE SCIENCE DVFA LIFE SCIENCE CONFERENCE_ 08:45 a.m . u Check-in 09:00 a.m. u Welcome Dr. Christa Bähr, CEFA, CFA, Chairwoman DVFA Life Science Commission, CB HealthCare 09:10 a.m. u Digital Transformation in Healthcare – Challenges & Opportunities Dr. Martin Pöhlchen, Partner, Alira Health - Presentation 09:45 a.m. u The Telematics Infrastructure: The Coming eHealth Revolution in Germany Christian B. Teig, CFO, CompuGroup Medical - Presentation 10:20 a.m. u Connected Diabetes Management - Presentation Julian Shapley, CSO, and Eric Cohen, IR, Cellnovo Group 10:50 a.m. u Coffee Break 11:10 a.m. u Increased Data Protection and Data Security Requirements under the New EU Data Protection Regulation - Presentation Dr. Lothar Ende, Partner, and Dr. Lutz Martin Keppeler, Senior Associate, Certified Specialist Lawyer for Information Technology Law, HEUKING KÜHN LÜER WOJTEK 11:45 a.m. u Panel I: New Business Modells Digital Health • Dr. Lutz Martin Keppeler, Senior Associate, Certified Specialist Lawyer for Information Technology Law, HEUKING KÜHN LÜER WOJTEK • Dr. Martin Pöhlchen, Partner, Alira Health • Karlheinz Schmelig, Managing Partner, Creathor Venture - Presentation • Christian B. Teig, CFO, CompuGroup Medical • Moderation: Dr. Klaus Suwelack, New Venture Lead Germany, Johnson & Johnson Innovation/Janssen 12:45 p.m. u Lunch 01:30 p.m. u Next Generation Sequencing & Big Data - Presentation Jason Gammack, Vice President Head of Marketing Life Sciences, QIAGEN N.V. 02:05 p.m. u The Health Revolution – Better Outcomes with Smart Data - Presentation Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE 02:40 p.m. u Coffee Break 03:00 p.m. u Panel II: Digital Health - A Capital Market Perspective • Kai Brüning, CEFA, Fundsmanager, apoAsset Management GmbH • Prof. Dr. Dr. Gerhard Lingg PhD, Chairman, imi mHealth Solutions Ltd. • Carsten Schmitt, Investment Banking, Renell Bank • Dr. Clemens Suter-Crazzolara, VP Product Management, Health, SAP SE • Moderation: Dr. med. Markus Manns, Chairman DVFA Life Science Commission, Equities Fund Manager, Union Investment Privatfonds GmbH 04:00 p.m. u Digital Health - Startup-Slam • Genomatix: Klaus May, Geschäftsführer - Presentation not released • HUMANOO: Roman Schweiger, CFO - Presentation • imi mHealth Solutions Ltd.: Lesli Wagstaffe, CEO • SynapCon: Dr. Julia Schüler, CBA, Investor Relations - Presentation not released • Moderation: Karlheinz Schmelig, Managing Partner, Creathor Venture 04:45 p.m. u Get-together Programme 13 June 2017 Clicking on the title will take you directly to the appropriate page.
  • 5. June 13, 2017 Digital Transformation in Healthcare – Challenges & Opportunities Dr. Martin Pöhlchen Partner, Germany
  • 6. 2 Strictly Confidential Strategy. Execution. Innovation. Alira Health is an international advisory firm providing integrated strategy, execution and innovation services for healthcare and life science companies. STRATEGY EXECUTION INNOVATION CORPORATE STRATEGY MARKET ACCESS MARKET RESEARCH COMMERCIAL DUE DILIGENCE IP AND PRODUCT PORTFOLIO STRATEGY REIMBURSEMENT AND PRICING HEALTH ECONOMICS REGULATORY STRATEGY LEADERSHIP EMPOWERMENT VALUATION AND FAIRNESS OPINION SELL AND BUY ADVISORY STRATEGIC PARTNERSHIP AND ALLIANCE MANAGEMENT GROWTH CAPITAL AND EXPANSION FINANCING IN- AND OUT-LICENSING SCIENTIFIC AND CLINICAL DUE DILIGENCE BUSINESS DEVELOPMENT PROJECT MANAGEMENT FOR REGULATORY SUBMISSION PRECLINICAL AND CLINICAL TRIALS CLINICAL COMMUNICATION AND EDUCATION NEW PRODUCT DEVELOPMENT NEW IP DEVELOPMENT CLINICAL AND SCIENTIFIC GUIDANCE ON INNOVATION INCUBATION OF BREAKTHROUGH TECHNOLOGIES
  • 7. 3 Strictly Confidential Our Knowledge. Your Power. Patient » Biotech and R&D Companies » RX Pharmaceuticals » Orphan Pharmaceuticals » Specialty Pharmaceuticals » Primary Care Therapies » Generics » Active Pharmaceutical Ingredients » Contract Manufacturing Organization » Contract Research Organization » Over the Counter » Consumer Care » Nutraceuticals » Cosmetics » Critical Care » Wound Care » Medical Imaging » Infection Control » Drug Delivery » Fluid Management » Cardiovascular » Neurovascular » Interventional Devices » Surgical Equipment » Orthopedics » In Vitro Diagnostics » Laboratory» Health Education » Health Data Analytics » Population Health Management » Telehealth » Electronic Medical Records » Big Data » Pharmacy Management Systems » Revenue Cycle Management » Precision Medicine » Wearables » Patient Monitoring » Telemedicine » Biostatistics » Drug Adherence » Drug & Device Combination Products » Companion Diagnostics Payers Healthcare Providers Product & Solution Suppliers Our expertise extends beyond the walls of convention and throughout every life science and healthcare sector.
  • 8. 4 Strictly Confidential Source: Berger, Roland (2016). Digital health market development 2015-2020 [USD bn]. 39 48 59 73 89 110 8 14 21 28 37 46 12 14 17 19 22 26 20 20 21 22 23 24 - 50 100 150 200 250 2015 2016 2017 2018 2019 2020 Wireless Health Mobile Health Telehealth EMR/HER +23% +41% +15% +4% 79 96 118 142 172 206> +21% p.a. The Digital Health industry is expected to grow at an annual rate >20 %.
  • 9. 5 Strictly Confidential Source: Berger, Roland (2016). Digital health market development 2015-2020 [USD bn]. Hypothesis: the digital healthcare revolution will come from R&D. DIGITAL VALUE POCKETS ALONG WITH THE VALUE CHAIN Understand how digitalization will impact your market segment R&D MANUFACTURING/ SUPPLY CHAIN MEDICAL/ MARKETING SALES Pharma Companies Digital Tools SMART DATA INDUSTRY 4.0 DIGITAL HEALTH MULTICHANNEL MANAGEMENT
  • 10. 6 Strictly Confidential The era of the Frank Zappa drug development strategy comes to an end. However, the non- responder problem persists.
  • 11. 7 Strictly Confidential From closed expert systems to informed customers Drug Development Monitoring Prevention Imaging Electronic Health Record Proteomics Metabolics Genomics Lab Management System Mobile Health Social Media Quantified Self Customer
  • 12. 8 Strictly Confidential ▪ Stronger engagement of IT companies in Digital Health ▪ New business models and cooperation in Digital Health • Cooperation with new players who directly connect R&D with payers and patients ▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in Digital Health
  • 13. 9 Strictly Confidential ▪ Stronger engagement of IT companies in Digital Health ▪ New business models and cooperation in Digital Health • Cooperation with new players who directly connect R&D with payers and patients ▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in Digital Health
  • 14. 10 Strictly Confidential Stronger engagement of IT companies in Digital Health (1) ▪ Verily: “Google of human systems biology” (March 3, 2016) • Andy Conrad, who heads up Verily (formerly known as Google Life Sciences), is working with a coalition of academic hospitals, physiscians, universities, and patient advocates to bring medical information into one place. Source: Future Genomics (March 3-4, 2016). La Jolla, US. https://www.fastcompany.com/3057455/verily-is-building-a-google-for-medical-information.
  • 15. 11 Strictly Confidential Stronger engagement of IT companies in Digital Health (2) ▪ Buzz: Apple plans to add 23andMe-style spit (May 8, 2015) • Apple has designs on the DNA sequencing sector. • The tech giant is reportedly working with research to make 23andMe-style DNA sequencing spit kits part of ResearchKit. • This platform turned every iPhone user into a potential study participant.
  • 16. 12 Strictly Confidential Stronger engagement of IT companies in Digital Health (3) ▪ IBM launches new health unit, teams up with Apple, J&J, Medtronic (April 13, 2015) • Launch of new company in Boston with 2,000 employees • Analysis of 700 million iPhone users • Acquisition of Explorys and Phytel to strengthen healthcare data analytics
  • 17. 13 Strictly Confidential ▪ Stronger engagement of IT companies in Digital Health ▪ New business models and cooperation in Digital Health • Cooperation with new players who directly connect R&D with payers and patients ▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in Digital Health
  • 18. 14 Strictly Confidential Source: FierceBiotech (June 5, 2017). http://www.fiercebiotech.com/medtech/ibm-watson-novartis-join-forces-breast-cancer. New business models and cooperation in Digital Health (1) ▪ IBM Watson, Novartis join forces on breast cancer (June 5, 2017) • The collaboration seeks to use real-world data to better understand the expected outcomes of various breast cancer treatments. Novartis will bring its breast cancer expertise, while IBM will contribute its data analytics and machine learning chops. • «As the industry shifts toward value-based care, it's critical for clinicians to understand the real- world outcomes of therapeutics on subsets of their patients, and our goal ultimately is to put those insights into oncologists' hands.»
  • 19. 15 Strictly Confidential New business models and cooperation in Digital Health (2) ▪ Merck KGaA and Peter Thiel’s Palantir join forces to speed up R&D (January 13, 2017) • Merck and Palantir have teamed up on big data to help the pharma industry combine its research with other bioinformatics to zero in on those cancer patients who could be helped the most by new meds, and then use this to help store up its R&D process. • Palantir, which also does business with GSK, said its data analytics would be used to help Merck «better, faster develop and deliver medicines to patients, commercialize new products and improve patient outcomes.»
  • 20. 16 Strictly Confidential New business models and cooperation in Digital Health (3) ▪ Teva taps IBM Watson for drug repurposing project (October 26, 2016) • Three-year collaboration to build a systematic process for drug repurposing using IBM Watson Health Cloud. • The allies plan to develop technologies that combine machine-learning algorithms, real-world data and human input to take some of the guesswork out of drug repurposing. • IBM will apply Watson’s natural language processing capabilities to unstructured health data trying to find correlations between molecules and diseases.
  • 21. 17 Strictly Confidential New business models and cooperation in Digital Health (4) ▪ FDA teams with Flatiron for real-world cancer data analytics project (May 27, 2016) • «Demonstrate the safety and efficacy of immunotherapies and other emerging anticancer drugs. • Flatiron, an oncology analytics shop that has received funding from Google Ventures and Roche. • Focus on the use of immunotherapies to treat advanced non-small cell lung cancer, an indication in which Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda are approved.»
  • 22. 18 Strictly Confidential New business models and cooperation in Digital Health (5) ▪ Novartis Pharmaceutical collaborates with Qualcomm in digital innovation with the Breezhaler™ inhaler device to treat COPD (January 5, 2016) • «The collaboration further supports Novartis' focus to empower patients making it easier for them to manage their own chronic disease by having near real time access to their own data on inhalation use.»
  • 23. 19 Strictly Confidential New business models and cooperation in Digital Health (6) ▪ AbbVie partners with Google's Calico on $1.5B R&D operation focused on aging (September 3, 2014) • AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely watched biotech upstart Calico on a new research operation that will cost up to $1.5B to get started.
  • 24. 20 Strictly Confidential New business models and cooperation in Digital Health (7) ▪ Data-gathering implantable chips to be tested in schizophrenia trial (November 13, 2015) • Transformation of wearables into implantables • Pierre Fabre tests a chip in an ongoing Phase II clinical trial of a schizophrenia drug in development. • The Swiss Federal Institute of Technology in Lausanne (EPFL): implantable biosensor chip to track pH, temperature, blood glucose, while keeping tabs on the concentration of any drugs administered to the individual.
  • 25. 21 Strictly Confidential ▪ Stronger engagement of IT companies in Digital Health ▪ New business models and cooperation in Digital Health • Cooperation with new players who directly connect R&D with payers and patients ▪ Enormous research budgets and stronger engagement of non-profit-organizations (NPOs) in Digital Health
  • 26. 22 Strictly Confidential Enormous research budgets and stronger engagement of NPOs in Digital Health (1) ▪ France plans $745M investment to build 235,000-genome-a-year sequencing operation (June 27, 2016) • The plan is to invest approximately $745M to build a network of sequencing and analysis centers capable of processing the equivalent of 235,000 genomes a year by 2020. • If successful, France will make genome sequencing part of routine healthcare for people with rare diseases and patients with metastatic, refractory cancers. The expectation is that as of 2020 France will sequence 20,000 rare disease patients and their parents.
  • 27. 23 Strictly Confidential Enormous research budgets and stronger engagement of NPOs in Digital Health (2) ▪ Horizon 2020: IMI2, Big Data For Better Outcomes (December 2015) • Provide a platform and resources for defining and developing enablers of the outcomes transparency evolution together with patients, payers, physicians, regulators, academic researchers, healthcare decision makers, etc. key enablers: – Definition of outcome metrics, protocols, tools to access high quality data – Methodologies and analytics to drive improvements – Digital and other solutions that increase patient engagement
  • 28. 24 Strictly Confidential Enormous research budgets and stronger engagement of NPOs in Digital Health (3) ▪ Medizininformatik (November 16, 2015, BMBF and extension June 2017) • Improve patient care and research via innovative IT Systems • These IT systems should enable usage of data from healthcare, biomedical and clinical research without considering locations and academic institutions. • 1st deadline: March 31, 2016, Consortia formed and approved August 2016
  • 29. 25 Strictly Confidential Enormous research budgets and stronger engagement of NPOs in Digital Health (4) ▪ Health Policy: National Rural Health Mission in India • A pilot program for 270 million school children to start a lifetime data collection, using mobile tablets for data entry and could storage for all health data. • Goals: determine the need for medical support, prevent epidemics, and provide analysis capabilities to aid in the understanding of health trends across the population. • Current figures: > 60,000 children enrolled Source: Collaboration between Indian Ministry for Health and SAP. http://www.forbes.com/sites/sap/2014/04/10/health-in-rural-india-will-never-be-the-same.
  • 30. 26 Strictly Confidential Enormous research budgets and stronger engagement of NPOs in Digital Health (5) ▪ ASCO: Health Information Technology Platform: CancerLinQ • «Big data is about to get bigger. CancerLinQ is assembling vast amouts of usable, searchable, real- world cancer information into a powerful database. This national initiative was inspired and informed by the cancer experts at ASCO, so it’s not merely an exercise in IT.» Source: ASCO & SAP (May 30, 2015) http://cancerlinq.org/.
  • 31. 27 Strictly Confidential Challenges (1) Source: Harvard Medical School, Partners Healthcare. Data analysis not in line with lab analysis Current manual methods Automated and scalable interpretation Classification of gene variants takes 20 minutes to 3 hours 0 1 10 100 1000 10000 100000 1000000 Variant Gene Panel Exome Genome Necessaryworkinghoursfor interpretationoftests Type of testHorizon
  • 33. 29 Strictly Confidential Challenges (3) ▪ Insufficient and already outdated e-Health legislation in Germany ▪ Missing Transparency Directive for health insurance data and usage for R&D similar to Clinical Trials Directive and other EU transparency guidelines ▪ Missing international, national and even regional harmonization concerning data security and public acceptance ▪ Convergence of legal regulations for „Medical Records“ in the areas of „e- and Mobile Health“ as well as new regulations for data exchange regarding „Medical Records“ in hospitals, etc. (for example for research purposes / Biotech R&D)
  • 34. 30 Strictly Confidential Challenges (4) ▪ Monolithic data silos and information gaps between biotech, pharma, CROs, patients and healthcare providers and payers ▪ Rising costs of interpretation of data versus wet lab costs and missing reimbursement ▪ Missing technical standards for efficient exchange of data among different industries ▪ Reglatory issues (see FDA) in terms of data veracity and data security ▪ Technical challenges of semantic Web 3.0
  • 35. 31 Strictly Confidential Challenges (5) ▪ Not enough well educated data scientists and executives to manage and implement Big Data analytics at the intersections of IT, healthcare and life science ▪ Public perception and unpredictable user behavior concerning Quantified Self Movement and data security ▪ Industry transformation in healthcare and life science from expert systems to customer oriented solutions
  • 36. 32 Strictly Confidential Referentenentwurf des Bundesministeriums des Innern Source: Kabinettsentwurf Januar 2017 (BMI). Entwurf eines Gesetzes zur Anpassung des Datenschutzrechtes an die Verordnung (EU) 2016/679 und zur Umsetzung der Richtlinie (EU) 2016/680 (Datenschutz-Anpassung- und Umsetzungsgesetz EU DSAnpUG-EU) A. PROBLEM UND ZIEL Am 25. Mai 2018 wird die Verordnung (EU) 2016/679 des Europäischen Parlaments und des Rates vom 27. April 2016 zum Schutz natürlicher Personen bei der Verarbeitung personenbezogegen Daten, zum freien Datenverkehr und zur Aufhebung der Richtlinie 95/46/EG (Datenschutz-Grundverordnung) (ABI. L 119 vom 4.5.2016, S.1) unmittelbar geltendes Recht in allen Mitgliedstaaten der Europäischen Union sein. Ziel der Verordnung (EU) 2016/679 ist ein gleichwertiges Schutzniveau für die Rechte und Freiheiten von natürlichen Personen bei der Verarbeitung von Daten in allen Mitgliedstaaten (Erwägungsgrund 10). Der Unionsgesetzgeber hat sich für die Handlungsformen einer Verordnung entschieden, damit innerhalb der Union ein gleichmäßiges Datenschutzniveau für natürliche Personen gewährleistet ist (Erwägungsgrund 13). Die Verordnung (EU) 2016/679 sieht eie Reihe von Öffnungsklauseln für den nationalen Gesetzgeber vor. Zugleich enthält die Verordnung (EU) 2016/679 konkrete, an die Mitgliedstaaten gerichtete Regelungsaufträge. Daraus ergibt sich gesetzlicher Anpassungsbedarf im nationalen Datenschutzrecht.
  • 37. 33 Strictly Confidential Questions for discussion What will be the first▪ «Uber moment» in Digital Healthcare? Will IT companies become the most innovative pharma companies or vice versa?▪ Will IT companies become the best health care insurance companies?▪ Which new▪ “convergent” business models and cooperation between pharma, healthcare and IT are possible, in particular in Germany and Europe? Who pays for what and who earns the▪ money? Where▪ is the patient?
  • 38. 34 Strictly Confidential Summary ▪ New business models and cooperations among different industries, payers, patients and healthy people are mandatory for success. ▪ A balanced individual/personalized access and public anonymized access to R&D, clinical data, health records, social media, health insurance data and open architecture is the key to success. ▪ Big returns on Digital Health investments takes more time as „big“ success is linked to development time lines of novel products/services in Life Science and Healthcare. ▪ Convergence of data protection and data security legislation are necessary. ▪ Veracity and validity of data in Digital Health applications and outdated data silos remain a challenge.
  • 39. 35 Strictly Confidential USA BOSTON 1 GRANT STREET, SUITE 400 FRAMINGHAM, BOSTON, MA, 01702 USA TEL +1 (774) 777 5255 BOSTON@ALIRAHEALTH.COM SPAIN CASAFRANCA 38, 08017 BARCELONA, SPAIN TEL +34 (93) 406 71 71 BARCELONA@ALIRAHEALTH.COM FRANCE 31 RUE DE MONCEAU, 75008 PARIS, FRANCE TEL +33 (0)1 44 54 96 23 FAX +33 (0)1 44 54 90 20 PARIS@ALIRAHEALTH.COM ITALY VIA CARLO OTTAVIO CORNAGGIA 10, 20123 MILAN, ITALY TEL +39 (02) 36680198 FAX +39 (02) 94 19 50 07 MILAN@ALIRAHEALTH.COM GERMANY KURFÜ̈RSTENSTRAßE 22, 80801 MUNICH, GERMANY TEL +49 (89) 416 14 22-0 FAX +49 (89) 416 14 22-99 MUNICH@ALIRAHEALTH.COM USA SAN FRANCISCO 101 MONTGOMERY ST, SUITE 2300, SAN FRANCISCO, CA, 94104 USA TEL +1 (774) 777 5255 SANFRANCISCO@ALIRAHEALTH.COM THANK YOU VERY MUCH FOR YOUR ATTENTION! Dr. Martin Pöhlchen, Partner, Germany martin.poehlchen@alirahealth.com
  • 40. 37 Strictly Confidential Digital Health Trends (Panel I discussion) ▪ Hypothesis 1: The barrier between healthy beings and patients will become obsolete. ▪ Hypothesis 2: From monitoring only to diagnosis, prevention and treatment ▪ Hypothesis 3: Personalized medicine and longitudinal studies become standard. ▪ Hypothesis 4: From “wellness” tracking to medical grade devices ▪ Hypothesis 5: From “classic” wearables to ingestible, transdermal and implantable sensors/medical devices and combinations
  • 41. Synchronizing HealthcareBerenberg Bank & Goldman Sachs German Corporate Conference, Munich Christian B. Teig, CFO 24 September, 2013 10th DVFA Life Science Conference 2017 The Telematics Infrastructure The Coming eHealth Revolution in Germany Christian B. Teig, CFO Frankfurt 13th June, 2017
  • 42. The coming secure communication arena in German healthcare Source: gematik 10th DVFA Life Science Conference 201713/06/20172
  • 43. The Telematics Infrastructure is based on the eGK The purpose of the German “Electronic Health Card” (eGK) is to improve the medical care of patients The eGK shall ensure that all healthcare providers have immediate access to all necessary medical information to deliver high quality and cost efficient care 10th DVFA Life Science Conference 201713/06/20173
  • 44. Gematik GmbH is behind the eGK / TI roll-out Facts Founded in January 2005 Owned by the 15 top organizations of the German health system (e.g. Bundesärztekammer, DAV - Deutscher Apothekerverband, Deutsche Krankenhausgesellschaft, GKV-Spitzenverband, KBV - Kassenärztliche Bundesvereinigung) Working closely with the Federal Ministry of Health Tasks Defining withing technical specifications for components, services and applications to be used in the Telematics Infrastructure Introduction, maintenance and enhancement of eGK electronic prescriptions and additional applications 10th DVFA Life Science Conference 201713/06/20174
  • 45. Realizing the Telematics Infrastructure has been a long process 2001 2003 Lipobay scandal 2005 Introduction of eGK by 1.1.2006 written into German Law EU tender „bIT4health“ Foundation of Gematik GmbH GesKVO „Plan B“ 2006 North Rhine- Westphalia eGK pilot region 2009 2010 Rössler at CeBIT: eGK is coming! 2012 Telematics Infrastructure tender process 10th DVFA Life Science Conference 201713/06/20175
  • 46. The largest IT project ever in German healthcare A total of 9 EU-wide tender processes have been completed: Online Rollout Level 1 (ORS-1): Testing of the Telematics Infrastructure in 2 test regions, each with 500 providers (doctors, dentists and hospitals). 3 contracts awarded through EU-wide tenders: LOS 1: Construction and operation of decentralized components and necessary infrastructure services; testing in Region South-East (Award: T-Systems) LOS 2: Construction and operation of decentralized components and necessary infrastructure services; testing in Region North-West (Award: Booz/CGM/KoCo consortium) LOS 3: Construction and operation of the central services and infrastructure surroundings for the Telematics Infrastructure (Award: Arvato Systems) G2 Cards: 5 contracts for a new generation of chip cards awarded through EU-wide tenders: LOS 1 & 2: Card Operating System (COS) for all card systems: eGK, HBA, SMC-B, gSMC-K and gSMC-KT (Awards: Giesecke & Devrient, T-Systems) LOS 3 & 4: Production of all relevant cards to be used in the ORS-1 test regions: eGK, HBA, SMC-B, gSMC- K and gSMC-KT (Awards: Bundesdruckerei, T-Systems) LOS 5: PKI infrastructure and associated services for Card Verifiable Certificates (Award: Atos) Scientific evaluation: 1 contract awarded through EU-wide tender for scientific evaluation of the two ORS-1 test regions (Award: Friedrich-Alexander-Universität) 10th DVFA Life Science Conference 201713/06/20176
  • 47. Tender process for 2 pilot regions (ORS-1) December 11 Gematik reaches a new decision to test the Telematics Infrastructure May 12 Bidder Contest October 12 Confirmation of five qualified vendors for the final offering November 12 Publication of specifications and request for final offers Tender process 10th DVFA Life Science Conference 201713/06/20177
  • 48. Two contracts were awarded in December 2013 November 13 Deadline for final offers December 13 Acceptance of tender for two partnerships 2014/2015 Test of the Telematics Infrastructure and Evaluation 2016 (est) Start of the rollout of the Telematics Infrastructure Tender process Winners announced 3 December 2013: Region North-West1: Booz / CGM / KoCo consortium Region South-East2: T-Systems 1: Schleswig-Holstein, Nordrhein-Westfalen, Rheinland-Pfalz 2: Sachsen, Bayern 10th DVFA Life Science Conference 201713/06/20178
  • 49. Project scope of ORS-1 Construction and operation of decentralized components and necessary infrastructure services: Phase 1: Insured Master Data Management (VSDM) Phase 2: Qualified Electronic Signature (QES) Secure communication between healthcare providers (KOM-LE) Tasks Planning and conception Recruit providers to participate in the pilots: Doctors (375), Dentists (125), Hospitals (5) Build a central VPN-access service and ensure its operations Develop, test and certify the necessary decentralized components (Konnektor (1x), Card terminals (10x )) Update and integrate existing doctor, dental and hospital software applications with the Telematics Infrastructure (13x) Rollout, service und support of the decentralized components for about 3 years 10th DVFA Life Science Conference 201713/06/20179
  • 50. The most important parties/products 10th DVFA Life Science Conference 201713/06/201710
  • 51. The full scale pilot in the Northwest region was launched in December 2016. All test installations have been successfully connected, more than 550,000 tests of the insured master data (VSDM) have been successfully carried out and information on more than 125,000 electronic health cards have been updated in real time. As a result, CGM has exceeded the project target of half a million online card tests more than two months before the end of the trial period. The installations and pilot operation are running without any material problems. Based on the successful results, gematik declared last week the Telematics Infrastructure to begin live operation 1 July 2017 Despite many delays and revised planning scenarios, the goal is still to have the nation-wide roll-out completed by 1 July 2018 as required by the eHealth law Current status 11 13/06/2017 10th DVFA Life Science Conference 2017
  • 52. Parallel to the gematik project, the German federal Ministry of Health began in 2014 the preparation of a new bill – “The eHealth Law” (Gesetzes für sichere digitale Kommunikation und Anwendungen im Gesundheitswesen) With clear majority, the bill was approved in the Bundestag on December 3rd 2015 and the new law became effective January 1st 2016 The eHealth law contains clear deadlines and financial incentives/penalties to ensure the timely roll-out of the Telematics Infrastructure in healthcare all over Germany in the 2016-2018 timeframe The German eHealth Law 10th DVFA Life Science Conference 201713/06/201712
  • 53. Rollout timeline in the eHealth law 1.1.2016 30.06.2016 The Law comes into force 1.1.2018 * If the deadline is not met, from 2017 on the expenditure in the budgets of the GKV SpiBu and the KBV must not exceed the expenditure of 2014 minus 1% each year until the action is performed (1% = app. 100 mio €) All pre-conditions for roll-out of VSDM must be in place* Nation-wide roll-out of the Telematik Infrastructure has to be completed* 1.7.2018 Doctors’ compensation will be reduced by flat rate of 1% if they are not using VSDM. 10th DVFA Life Science Conference 201713/06/201713
  • 54. VSDM (eligibility check and update of insurance data) is the core service of the Telematics Infrastructure. Emergency Data Set (blood type, chronic diseases, allergies etc.) stored on the electronic health card. Service must be available beginning 2018. Doctors who create and maintain such datasets on behalf of patients will be compensated (no amount given) Medication plan (for patients with more than 3 current prescriptions). Service must be available from October 2016 in paper form and then in the ‘medium term’ (Mittelfristig) be available over the electronic health card. Electronic letters (Medical reports, referrals and discharge letters between ambulatory doctors and hospitals). Doctors get an incentive of 55 cents per medical report sent electronically and 50 cents per discharge letter received electronically in 2016 and 2017. Hospitals get 1 Euro per discharge letter sent electronically from 1 July 2016. From 2018, the incentives for electronic letters will only be paid if the transmission is done over the telematics infrastructure (no amount given). Telemedicine. Electronically transmitted radiology reports will be compensated beginning 1 April 2017 (no amount given). The regions also has the mandate to consider additional paid telemedicine services. Services prescribed in the eHealth law 10th DVFA Life Science Conference 201713/06/201714
  • 55. Potential additional products and services Nr. Product / Service Customer / User Source 1 Elektronischer Entlassbrief Krankenhaus eHealth Law 2 Konsiliarische Befundbeurteilung Ärzte eHealth Law 3 Notfalldatensatz Zahnärzte eHealth Law 4 Arzneimitteltherapiesicherheit (AMTS) Ärzte / Apotheke eHealth Law 5 Medikationsplan Ärzte / Apotheke eHealth Law 6 Sicher Übermittlung elektronischer Briefe Ärzte / Krankenhaus eHealth Law 7 Organsspendeausweis Krankenhaus gematik 8 Elektronische Fallakte Ärzte / Krankenhaus gematik 9 Elektronisches Patientenfach Ärzte / Krankenhaus gematik 10 Elektronische Patienttenquittung Ärzte / Krankenhaus / Zahnärzte gematik 11 Fachdienst VSDM Telematik Infrastruktur gematik 12 VPN-Zugangsdienst Telematik Infrastruktur gematik 13 Patientenverfügung Ärzte / Krankenhaus CGM 14 Impfstatus und Impfplanung Ärzte CGM 15 Zahnstatus Zahnärzte CGM 16 Ernährungsplan Ärzte CGM 17 Elektronische Patientenakte Ärzte / Krankenhaus CGM 10th DVFA Life Science Conference 201713/06/201715
  • 56. Potential additional products and services (2) Nr. Product / Service Customer / User Source 18 Laborbefund Ärzte / Krankenhaus CGM 19 Röntgenbefund Ärzte / Krankenhaus CGM 20 AU - Bescheinigung Ärzte CGM 21 KH Einweisung Ärzte / Krankenhaus CGM 22 Heil- und Kostenplan Zahnärzte CGM 23 .. weitere Formulare Ärzte / Krankenhaus CGM 24 One-Klick Abrechnung (der KBV) Ärzte CGM 25 Zuzahlungsinformationen Ärzte / Krankenhaus / Zahnärzte CGM 36 Teilnahme an Selektivverträgen Ärzte / Krankenhaus CGM 27 Arzneimittelkonto Ärzte / Krankenhaus CGM 28 Software Assisted Medicine - Diabetes Ärzte / Krankenhaus CGM 29 Software Assisted Medicine - Herzinsuffizienz Ärzte / Krankenhaus CGM 30 Software Assisted Medicine - Rückenschmerz Ärzte / Krankenhaus CGM 31 Software Assisted Medicine - Depression Ärzte / Krankenhaus CGM 32 Software Assisted Medicine - Rauchentwöhnung Ärzte CGM 33 Software Assisted Medicine - Gesundes Gewicht Ärzte / Krankenhaus CGM 34 Software Assisted Medicine - Blutdruckstabilisierung Ärzte / Krankenhaus CGM 10th DVFA Life Science Conference 201713/06/201716
  • 58. Data center B 13/06/2017 10th DVFA Life Science Conference 201718 The Danish Health Data Network (SDN) and VANS network User User User User User User User User Secured connections between secured local networks Datacenters owned by MedCom, operations outsourced by EU tender (currently Netdesign A/S) MPLS Internet VPN Fixed lines Secure messaging (EDI) via private VANS operators KMD or Highjump Data center A KMD HighJump
  • 59. Evolution of services in the network 19 2001 2003 The “Good EDI letter” defined by MedCom 2005 Sundhed.dk – the Danish eHealth portal Citizens’ access to their own prescriptions EDI becomes XML ‚e-journal‘ -wider access to journal data for citizens 2007 Telemedicine is deployed nationwide 2009 2011 2014 Shared Medication Record (FMK) New standards HL7 - IHE 13/06/2017 10th DVFA Life Science Conference 2017
  • 60. 13/06/2017 10th DVFA Life Science Conference 201720 Evolution of GP electronic communication 0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 1,8 92 93 94 95 96 97 98 99 20 01 02 03 04 05 06 07 08 09 10 11 12 E-Prescriptions = 90 % Disch Letters = 100 % Lab reports = 100 % Lab test Orders = 100 % E-Referrals = 95 % MedCom Messages / Month (in million) +6000 doctors, pharmacies, municipalities and hospitals 65 IT vendors 6 milllion messages/month 15% growth/year 70-90% of all documents Source: MedCom
  • 61. 13/06/2017 10th DVFA Life Science Conference 201721 Denmark’s e-Health portal introduced in 2003 Online Electronic Health Record from hospitals Cross-sectorial personal electronic medicine profile Overview of personal medical history since 1977 (list of contacts with hospitals) Overview of contact with primary sector clinics since 2003 Online organ donor registration ’My log’ (lets the patient see which health professionals have accessed their personal data)
  • 62. 13/06/2017 10th DVFA Life Science Conference 201722 FMK – Shared medication data base from 2014
  • 63. 13/06/2017 10th DVFA Life Science Conference 201723 Norsk Helsenett (Norwegian Health Network) Rolled out nationwide in 2006-2007 to all doctors and hospitals Transformed to a state-owned enterprise in 2009, owned by the Ministry of health and care services Runs as a government monopoly with approximately 150 employees Backbone network, operations, support and consultancy services are mostly subcontracted through EU tenders In addition to all healthcare providers, the network is also open to about 100 connected, third-party service providers (hereunder CGM) All activity is governed by the «Code of Conduct for information security in the healthcare, care, and social services sector»
  • 64. 13/06/2017 10th DVFA Life Science Conference 201724 Sjunet (Swedish Health Network) Since 1998 the Sjunet application has been connected to virtually all Swedish hospitals and Primary Care Centres Sjunet is offered by Inera AB Inera is a common service provider for county councils in Sweden 3 ways to connect to Sjunet: Dedicated fixed line from Inera 3rd party local network connected to Sjunet IPSEC-encrypted VPN- connection via Internet
  • 65. Austria and Germany have similar eHealth strategies 25 Political discussions from 2003 ELGA GmbH e-card GesundheitsInformationsNetz GINA-Box eHealth law 2012 E-Medikation ….etc….. 13/10/2017 10th DVFA Life Science Conference 2017 Political discussions from 2001 gematik GmbH eGK Telematik Infrastruktur Konnektor eHealth law 2015 Medikationsplan mittels eGK ….etc….
  • 66. 13/06/2017 10th DVFA Life Science Conference 201726 Where we stand Germany is late w.r.t. eHealth So is Austria More pragmatic technology and security solutions have enabled the healthcare economies in Scandinavia to become networked 10-20 years ago However, many issues related to identification, authentication and authorization remain unresolved in these early countries Based on the eGK and Telematics infrastructure, Germany now has an excellent opportunity to leapfrog to the forefront of eHealth The next 3 years will see a late but powerful eHealth revolution in Germany There is reason to be optimistic!
  • 67. 10th DVFA Life Science Conference 2017 Thank you for your attention! CompuGroup Medical SE Investor Relations Maria Trost 21 56070 Koblenz www.cgm.com Phone: +49 (0) 261 8000-6200 Email: investor@cgm.com 13/06/201727
  • 69. Page 2 D i s c l a i m e r This confidential document and the information contained in this document (the “Presentation”) constitutes neither an offer for sale or subscription nor a solicitation of a purchase or subscription order for Cellnovo shares in any country. No offer of shares is made, or will be made in France, before obtaining a visa from the Autorité des Marchés Financiers (the “AMF”) on a prospectus comprising a registration statement (document de base) and securities note (note d’opération) that will be submitted to the AMF. In particular, this Presentation does not constitute an offer for sale of securities or any solicitation of a purchase or subscription order for securities in the United States or by U.S. persons (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). Cellnovo shares may be only offered or sold in the United States pursuant to an effective registration statement under the Securities Act or under an exemption from the registration requirement of the Securities Act. Cellnovo shares have not been and will not be registered under the Securities Act, and Cellnovo has no intention of making any public offering of its shares in the United States. This Presentation does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the “Prospectus Directive”). Its dissemination may be governed by specific regulations in certain countries. Persons in possession of this Presentation should therefore acquaint themselves and comply with any local restrictions. No action has been taken or will be taken for the purpose of enabling a public offering of securities requiring the publication by Cellnovo of a prospectus in a Member State other than France. Consequently, the Cellnovo shares may not and will not be offered in any Member State other than France, except in accordance with the exceptions set forth in Article 3.2 of the Prospectus Directive or in other cases not requiring publication by the Company of a prospectus pursuant to Article 3.2 of the Prospectus Directive or other applicable regulations in that Member State. Regarding the United Kingdom, this Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 and therefore it is intended to be delivered solely and for information purposes only to persons who (i) are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as currently in effect, hereinafter the “Financial Promotion Order”), (ii) are referred to at Article 49(2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an Presentation or incitement to engage in investment activities (within the meaning of section 21 of the Financial Services and Markets Act 2000) in the context of the issuance or disposal of securities may legally be extended, directly or indirectly (all such persons being collectively named “Authorised Persons”). This Presentation may not be used by any person who is not an Authorised Person. By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the Presentation.
  • 70. Page 3 A M a n a g e m e n t Te a m W i t h A S u c c e s s f u l Tr a c k R e c o r d Dr. Sophie Baratte CEO l 20 years experience in Sales & Marketing functions in the medical technology sector, including Sorin Group l Served as CEO of CIT, General Manager for the In Vitro Diagnostics branch of Johnson and Johnson in France and senior EMEA Sales & Marketing Director for Lifecell Engineer, PhD in biotechnology and MBA Erwan Martin CFO l 20 years experience in finance and in biotechnologies l Former CFO of Genomic Vision, co-founded Cytomics Pharmaceuticals, served as project manager at Syndex Julian Shapley CSO, Founder l NASA experience l Founder of Cellnovo since 2008 MBA at Warwick Business School Ph.D. in micro-fluidics at Cardiff University John Brooks Chairman l Serverd as CEO and Founder of Insulet l and as CEO of Joslyn Diabetes center l Over 30 years of experience in the medical device industry in diabetes Javaid Masoud CTO l Served at Medtronic and at Sorin Group in Senior director roles, for wireless technologies, embedded firmware development for implantable cardiac defibrillators, wireless communication protocol, embedded firmware for implantable devices, and software for external instruments
  • 71. Page 4 C e l l n o v o i n a N u t s h e l l • Cellnovo develops and commercialises a disruptive Insulin Micro-pump • A $2.5Bn market: growing and well reimbursed Focused on Type 1 diabetes with potential for larger Type 2 market • Addressing clear market needs The only real time data device, for better patients outcome • Unique Accuracy and Safety features • A clearly defined global strategy supported by strategic partners - Roche: contract for Blood Glucose Measurement - Flex: manufacturing partner - Air Liquide: major distribution partner • Road map towards Artificial Pancreas and smartphone • IPO on Euronext Paris on July 2015: €32.4m raised to date • Private placement of €5.4m achieved in Q3 2016 The First Connected All-in-one Diabetes Management System 1. North America+ Main European countries, Medtronics, Investor Conference, June 2014
  • 72. Page 5 • Informing payers of compliance to treatment • Lower pricing than other Wearable pumps C e l l n o v o , a b r e a k t h r o u g h i n I n s u l i n D e l i v e r y, f o r a l l s t a k e h o l d e r s Driving Efficiency and Better Outcomes Driving Savings • The ultimate wearable pump • Requested by patients • E- connected for family’s peace of mind • Real time information to drive Better Patients Outcomes • The un-equalled accuracy and safety of drug delivery in micro-pumps Cost Effective Patients support • Effective patients’ communication and trouble shooting, based on Real time back-end data Freedom and peace of mind The only E-connected, Accurate, Wearable insulin pump
  • 73. Page 6 A S t r o n g U p c o m i n g N e w s F l o w 20182017 Flex industrialize Cellnovo insulin cartridges Q2 Q3 Q4 Commercial agreements with AP Type Zero Diabeloop enters CE marking clinical trial New distribution partners New Blue Tooth Android System 510K clearance Artificial Pancreas filling of CE marking First sales in the US CE marking of “Smartphone” Connection of Blue Tooth BGM Type Zero studies in the US and in EU Artificial Pancreas commercialization in the EU Cellnovo completely outsources manufacturing Connection of CGM New food library ✔ ✔ ✔ All the fundamentals in place Huge growth and introduction of more breakthrough technologies Production Product Development Commercialization Artificial Pancreas Timeline
  • 74. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 75. Page 8 Ty p e 1 : A l a r g e m a r k e t , w e l c o m i n g i n n o v a t i o n T1 Patient Market* MDI Tubed Pump Micro Pump US % Patient Use 70% 25% 5% EU % Patient Use 85% 12% 3% Market Size $2 B $400 M Growth Rate <5% 40% Market Players Pumps are providing short and long term benefits to patients, despite low penetration * company estimates
  • 76. Page 9 E a s y t o A c c e s s w i t h F a v o u r a b l e R e i m b u r s e m e n t Cellnovo micro-pump has access to public funding across many geographies Market Durables 3 Day disposables USA $4,500 $15 UK £2,750 £11.30 France €2,340 €16.65 Italy €4,800 €18 Germany €2,800 €12 1. Source : Company Simple market access based on Existing codes • Market access provided by CE marking o Already CE marked • Market access provided by 510K Clearance o Expected end of 2017 • Reimbursement using traditional pumps codes o Established codes in each countries o Describing a durable pump and a consumable part • Reimbursement using CPT code 1 Tube pumps’ prices
  • 77. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 78. Page 11 C e l l n o v o : A G a m e C h a n g e r f o r I n s u l i n P u m p Te c h n o l o g y The perfect combination between a new generation of patch pump and a mobile handset to allow the best accuracy and a 24/7 health remote monitoring Intuitive operation, wireless Internet connectivity and real-time tracking = all industry firsts • The insulin reservoir • Pumping mechanism • Occlusion sensor • High resolution, full colour touch screen • GSM Modem • Micro SD port • Apps friendly • Roche BG Meter integrated • Bolus calculator • Real-time data • Automated capture of data and transmission • Analytics and trends • Stakeholders access• Pump microprocessors and memory • Rechargeable battery • Accelerometer • Precision reservoir sensor Insulin Cartridge Mobile Handset Online Wireless DurablesDisposables
  • 79. Page 12 C e l l n o v o B e n e f i t s c o m p a r e s p o s i t i v e l y t o t h e o t h e r m i c r o - p u m p s for Additional Comfort Better Outcome and Peace of Mind Better COGS and Eco-friendly Device High Quality of Treatment A Key Feature for All Intuitive Usage E-Health in real time Higher Accuracy of delivery Disposable plastics Detachable Enhanced Safety Touch Screen Color Handset
  • 80. Page 13 C e l l n o v o , t h e d a t a s o l u t i o n f o r b e t t e r o u t c o m e CLINIC & CLINICIANS PATIENTS’ FAMILIES PAYER Reducing pressure on National Health Systems’ resources Peace of Mind with no intrusion in patients’ life with apps and portal access • Informs and Guides the patients • Informs the family • Generates bespoke alarms on Family’ Smartphones Increasing Efficiency and Generating better outcomes • Prioritization of treatments • Cost reduction • Productivity • Reactivity • Cost reduction • Care improvement • Reduction of complications • m-health: modernized healthcare system AND PARTNERS • Informed trouble shooting calls • Easy logistics
  • 81. Page 14 C e l l n o v o s y s t e m i s m o s t a c c u r a t e p a t c h p u m p i n d r u g d e l i v e r y Not all micro-pumps are equal Cellnovo: 2 part pumping system -100,0% -50,0% 0,0% 50,0% 100,0% 0 50 100 150 200 Flow rate error Observation duration (minutes) Omnipod Percentage error vs. observation window (Time based). -100,0% -80,0% -60,0% -40,0% -20,0% 0,0% 20,0% 40,0% 60,0% 80,0% 100,0% 0 50 100 150 200 Flow rate error Observation duration (minutes) Cellnovo Percentage error vs. observation window (Time based). Cardiff University, UK- Jenna L Bowen and Chris J Allender - Trumpet curves for a typical Cellnovo and OmniPod™ patch pump device showing the maximum positive and maximum negative flow rate error (green solid lines) and the average flow rate error (red dotted line) for 2, 5, 11, 19 and 31 pulses. o Accuracy of the Wax-powered pumping mechanism o Superiority of durable electronics and Drop-by-drop alterations control system A difference explained by the design Traditional patch pump: fully disposable, all in one system o Low cost, low sophistication electronics o Flat rate pumping mechanism
  • 82. Page 15 A c c u r a c y, t h e r e s u l t o f a u n i q u e m e c h a n i s m o f d e l i v e r y The core technology: the paraffin wax Micro-actuator The expansion of heated paraffin wax serves as mechanism to push a piston against a membrane, thereby creating a pumping mechanism OCCLUSION VALVE INLET VALVE OUTLET VALVE PUMPING CHAMBER GEARING PISTON DIODE WAX Cool Wax Heated Wax After melting +15% Volumetric Expansion (%) Solid phase Liquid phase IP protected until 2035 Wax Micro Actuator Displacement Sensor Micro- Valve Cyber security
  • 83. Page 16 S a f e t y s y s t e m s o n b o a r d Product Time to Occlusion Alarm Missed Insulin (U) Cellnovo 24.12 2.02 Omnipod Gen2 41.35 3.46 Medtronic 57.49 4.82 Animas Vibe 44.09 3.68 Roche Spirit Combo 28.47 2.39 Best in class in case of occlusion Intelligent Delivery SystemDelivery Sensor Automatic release mechanism Temperature risk alarm Insulin delivery alarms 72-hour Expiry alarm Encryption The pump’s electronics, to bring safety to a new level
  • 84. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 85. Page 18 C o n s u m a b l e : l a r g e s c a l e p r o d u c t i o n w i t h F l e x • High volume automation and manufacture • Stacked basic components, suitable for high cavity moulding Flextronics’ Mass productionCellnovo’s Limited production NowUntil Q2 2017 IC capacity Per production line Capacity pa 650,000 IC capacity 2015 Capacity pa 50,000 From Cellnovo’s R&D workshop To flex Austria in Q2 2017 Followed by producing in a low labor cost country in Q1 2018. Design to cost to further optimize COGS1 2 3 4 1 2 3 4 Increasing volumes of consumable parts Reducing COGS
  • 86. Page 19 D u r a b l e e l e m e n t s : a s i m p l e p r o d u c t i o n r o a d m a p The mid-term manufacturing strategy favors Outsourcing Cellnovo to remain lean with low Overheads Relatively low production volumes are required: each patient needs 2 pumps and 1 handset The manufacturing roadmap will aim at decreasing COGS by 2 folds by mid 2018 2018 : Replaced by a smartphone tablet 2017-mid 2018: Assembled by Cellnovo Production strategy 2017: Assembled by Cellnovo • PCB made by Sony The Micro-Pump The Handset Mid-2018: outsourced * * Picture non-contractual• PCB made by Sony
  • 87. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 88. Page 21 C e l l n o v o ’ s c o m m e r c i a l r o a d m a p A network with direct sales forces and experienced distributors Objective 2020 horizon: 45,000 patients 2014 System introduction through proprietary sales force in the UK and France 2016 Expansion into other major European countries using specialized distributors : Netherlands, Italy 2017 Expansion into Spain, Ireland, Greece, Israel, .. 2016 510k submission 2017 Launch in the US Launch in Canada First countries in L.A. 2017 Launch in Australia/NZ Launch in Hong Kong 2018 Launch in India 2019/2020 Launch in China Europe USA China/Asia Direct Distribution (UK, France) Air Liquide Santé network: Benelux, Italy Expansion to new European countries
  • 89. Page 22 C e l l n o v o U S S t r a t e g y Targeted launch Q4 2017 – Q2 2018 • Targeting main KOL • Regional complementarity • Payers complementarity Objective: demonstrate the business case Patients’ preference / Payers’ acceptance / E-health benefits • Light structure to guarantee o Leadership o Sales o Training o Marketing o H&E US National launch Q3 2018 • Through an established partner Benefits Price Cellnovo will reinforce the distributor effort by putting in place its own organization 5 Main Cities Cellnovo Structure Pricing Strategy 2 to 3 Distributors
  • 90. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 91. Page 24 C e l l n o v o , t h e s y s t e m o f c h o i c e f o r A r t i f i c i a l P a n c r e a s • US Well proven program, with 215,501 hours of clinical trial • Data on 30 patients “80% of hours on target” • CE marking early 2018, followed by EU launch • “Natural” EU partner o Commercial contract pending • WW commercial license agreed • Integration of the product on-going • Clinical studies in discussion • Best placed US partner All projects with Dexcom G5 • French atomic center mathematicians and 12 major teaching hospitals in France CONTINUOUS GLUCOSE SENSOR CONTROL ALGORITHM • Automatic adjustments of the insulin delivery • Based on expert Software and Continuous Blood Glucose reading • Un-Equaled Quality of Life • Less Deadly Complications The potential to be N1 Artificial Pancreas using a Micro pump Artificial Pancreas, the next break through in Diabetes management Cellnovo ‘s partners Commercial strategy
  • 92. Page 25 C o m p a r i s o n Ty p e Z e r o / M e d t r o n i c • Founded in 2005, spin-off from UVA • In clinical trials since 2011 • The most published Artificial Pancreas SW • Well financed by the NIH • CGM: G5 Dexcom Type Zero, a Strong partner TypeZero inControl Medtronic PID-IFB Paper Ly, Buckingham et al Diabetes Care, 2016 Ly, Buckingham et al DT&T, 2016 Control 24/7 – 85 days and nights Overnight only – 55 nights Average BG Overnight 128 mg/dl 132 mg/dl Overnight time within 70-180 mg/dl 90.3% 79.9% Overnight time within 70-150 mg/dl 76% 66.4% Overnight time below 70 mg/dl 1.4% 5.4% 24/7 time within 70- 180 mg/dl 78.6% n/a 24/7 time below 70 mg/dl 1.8% n/a
  • 93. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 94. Page 27 K e y F i n a n c i a l s o f t h e G r o u p - S a l e s • 667 systems shipped in total since launch with 38 new systems in Q1 2017 • Production Capacity of Insulin Cartridges constrained at 50,000 per year before the transfer to Flex • On April 2017, Flex has completed the first commercial batch of consumables for its diabetes management system. Annual Quarterly – 3 months 2016 2015 Q1 2017 Q1 2016 Sales (in Euros) 1,416,744 608,125 185,592 435,209 At full capacity, the Flex’s production line is able to produce 600,000 insulin cartridges per year. • A cash position of €5,8 million at March 31, 2017 • Cellnovo is in the final stage of securing a Loan facilities with a first draw down of at least €5M. Strong 2016 sales growth / Sales constrained in Q1 2017 by limited production capacity
  • 95. Page 28 K e y F i n a n c i a l s o f t h e G r o u p – P & L Simplified P&L in K€ – IFRS FY2016 FY2015 Revenues Sales 1,419 609 Operating expenses o/w Costs of production (6,647) (5,845) o/w Research and Development (2,366) (3,244) o/w Sales & Marketing (2,545 (1,557) o/w General & Administration (4,476) (5,135) Total Operating Expenses (16,034) (15,781) Other operating income and expenses 2 551 Operating profit / (loss) (14,614) (14,622) Financial result (559) (969) Income tax 625 1,126 Net profit/(loss) (14,549) (14,464)
  • 96. Page 29 C e l l n o v o o n t h e m a r k e t Shareholding structure as of September 30th 2016 Financial calendar • Market listed on Euronext (Euronext Paris) • Share price: €5,3 (April 30th, 2017) • Number of shares: 12,070,597 (March 31th , 2017) • Market Cap: €64 million (April 30th , 2017) Stock market information Events Date 2016 FY sales Tuesday January 31, 2017 2016 FY results and 2017 Q1 sales Wednesday April 26, 2017 2017 H1 sales Tuesday July 25, 2017 2017 H1 results Wednesday September 27, 2017 2017 Q3 sales Tuesday October 31, 2017 Board of Directors • John Brooks, Chairman • Sophie Baratte, CEO • Julie Drapier, Aliad • Marie Landel, Independent • Sofia Loannidou, censor, Edmond de Rothchild I.P. • Raj Parekh, Advent Venture Partners • Holger Reithinger, Forbion Capital Partners • Rémi Soula, Independent • Raphael Wisniewski, Edmond de Rothchild I.P. Forbion 14,5% EDRIP 14,3% Healthcare Ventures 9,4% Advent International 9,4% NBGI 5,5% Omnes Capital 4,1% Air Liquide Investissement 3,5% Autres 39,4% Others
  • 97. Agenda 1. Positioned on a fast growing, accessible market 2. A unique technology 3. A company well placed on COGS 4. An aggressive commercial strategy 5. The next breakthrough: the Artificial Pancreas 6. Financials 7. Conclusions
  • 98. Page 31 C e l l n o v o ’ s K e y S e l l i n g P o i n t s Completed since the IPO ✔ ✔ ✔ ✔ Breakthrough technology on a high growth market Cost advantages over current wearable pumps Real time data for Patients and HCP benefits US market entry by end 2017 Patients superior comfort of use First Artificial pancreas on the market early 2018 Set for large scale commercialisation
  • 99. Increased data protection and data security requirements under the new EU Data Protection Regulation 13 June 2017 Dr. Lothar Ende Dr. Lutz M. Keppeler DVFA Life Science Conference 2017
  • 100. • Heuking Kühn Lüer Wojtek • Overview on data flows – simple case of a consumer device 13.06.2017 DVFA Life Science Conference 2017 2 Icon made by Freepik from www.flaticon.com Wearables Smartphone/App of a user (medical device?) Provider of Operating System/Smartphone Cloud Cloud Provider ABC Ltd. XYZ Inc. Health insurance Hospital
  • 101. • Heuking Kühn Lüer Wojtek • Overview on data flows – simple case of a professional medical device 13.06.2017 DVFA Life Science Conference 2017 3 Icons made by Freepik from www.flaticon.com Cloud Provider? Own Servers? Health insurance External Physician Provider of Medical Device?
  • 102. • Heuking Kühn Lüer Wojtek • General Requirements under the GDPR 13.06.2017 DVFA Life Science Conference 2017 4  Duty to examine the lawfulness of processing of personal data according to Articles 6 and 9 GDPR (Every act of data processing must be based on a Section which allows it)  Compliance with the provisions for declarations of consent according to Articles 7 and 8 GDPR  Transparent information of customers on the data processing (with respect to customers and employees) according to Articles 13,14 GDPR  Duty to delete data, the storage of which is no longer admissible (Art. 17 GDPR)  Duty to make data provided by customers/employees available– in a conventional format – to the customer/employee upon request (right to data portability) according to Art. 20 GDPR
  • 103. • Heuking Kühn Lüer Wojtek • General Requirements under the GDPR 13.06.2017 DVFA Life Science Conference 2017 5  Compliance with the provisions on data protection by design and data protection by default Art. 25 GDPR  Obligation regarding data protection measures according to the state of the art (Art. 32 GDPR - “data security by design”)  Reports of data outflows after an IT security incident according to Art. 33 GDPR  Compliance with the provisions in the case of the outsourcing of a data processing to a service provider and other processors according to Art. 28 GDPR, including the provisions on the transmission of data outside the EU or to subsidiary/sister companies)
  • 104. • Heuking Kühn Lüer Wojtek • Special rules on health-related data 13.06.2017 DVFA Life Science Conference 2017 6  Special acts are applicable, particularly for health-related data:  Law on medical products (Medizinproduktegesetz – Sec. 2 para. 4)  Art. 9 paras. 1, 2 (a) GDPR (specific higher requirements for declarations of consent on health-related data)  Special requirements on personal data of clinical studies (Sec. 40 para. (1) No. 3 c) German Drug Law - Arzneimittelgesetz)  Special data protection requirements in the public healthcare sector (Social Code - Sozialgesetzbuch V and X)  Wide interpretation of the term “health-related data”  Disclosure of health-related data by physician or by dentist, veterinarian, pharmacist is considered as crime (imprisonment not exceeding one year or a fine) (Sec. 203 German Criminal Code - Strafgesetzbuch)
  • 105. • Heuking Kühn Lüer Wojtek • New dimension of administrative fines 13.06.2017 DVFA Life Science Conference 2017 7  Currently only a maximum fine of EUR 300,000 can be imposed  Fines in the amount of up to EUR 10/20 million or 2/4% of the worldwide annual turnover  Adequate to threaten international IT-Corporations / Dangerous for medium size companies  Software/Medical devices are often not designed to comply with data protection requirements
  • 106. • Heuking Kühn Lüer Wojtek • Basic concepts of data protection law according to the GDPR 13.06.2017 DVFA Life Science Conference 2017 8  The definition of „Personal data“ is defined extremely broad  even dynamic IP-addresses must be considered as personal data  Definition of „data processing“ is extremely broad  Each controller must for each step of data processing comply with all before mentioned requirements  Joint controllership is possible (necessity to define who fulfils which requirement)
  • 107. • Heuking Kühn Lüer Wojtek • Compliance Obligation 13.06.2017 DVFA Life Science Conference 2017 9  (…) the controller shall implement appropriate technical and organisational measures to ensure and to be able to demonstrate that processing is performed in accordance with this Regulation. Those measures shall be reviewed and updated where necessary (Art. 24 GDPR)  Each controller and, where applicable, the controller's representative, shall maintain a record of processing activities under its responsibility (Art. 30 GDPR)  Where a type of processing (…) likely to result in a high risk (…) the controller shall, prior to the processing, carry out an assessment of the impact of the envisaged processing operations on the protection of personal data (Art. 35 GDPR) = High documentation obligations and, as a result, a reversal of the burden of proof
  • 108. • Heuking Kühn Lüer Wojtek • IT-Security  … the controller and the processor shall implement appropriate technical and organizational measures to ensure a level of security appropriate to the risk (Art. 32 GDPR – data security by design)  Medical devices will have to be designed in a way that allow the processor to establish and maintain necessary IT-security level  if not – defect, product liability  What is appropriate?  (…) taking into account the state of the art, the costs of implementation and the nature, scope, context and purposes of processing (…)  Not defined by case law − Recommendation: Usage of recognized standards, such as ISO 2700x; BSI- Grundschutz-Kataloge; „Standard-Datenschutz-Model („SDM“) − Usually three steps: Risk analysis; Choice of adequate measures; Implementation  Conclusion: Be pragmatic but document and explain why 13.06.2017 DVFA Life Science Conference 2017 10
  • 109. • Heuking Kühn Lüer Wojtek • Obligations to notify data breach  GDRP: In the case of an IT security incident, an obligation to "promptly" notify the responsible data protection authority (Art. 33 GDPR) and a message towards each affected data subject (Art. 34 GDPR) is required  German IT-Security Law: Notification to the Federal Office for Information Security; only applicable on „provider of critical infrastructure” (like cloud service provider; hospitals)  Parallel to this, ad-hoc publicity for listed companies  Consequence: definition of the reporting process,  Verification of the necessity to report  Coordination of various departments (including public relations) and various undertakings 13.06.2017 DVFA Life Science Conference 2017 11
  • 110. • Heuking Kühn Lüer Wojtek • Berlin Kurfürstendamm 32 10719 Berlin/Germany T +49 30 88 00 97-0 F +49 30 88 00 97-99 Chemnitz Weststrasse 16 09112 Chemnitz/Germany T +49 371 38 203-0 F +49 371 38 203-100 Düsseldorf Georg-Glock-Straße 4 40474 Düsseldorf/Germany T +49 211 600 55-00 F +49 211 600 55-050 Frankfurt Goetheplatz 5-7 60313 Frankfurt a. M./Germany T +49 69 975 61-0 F +49 69 975 61-200 Hamburg Neuer Wall 63 20354 Hamburg/Germany T +49 40 35 52 80-0 F +49 40 35 52 80-80 Cologne Magnusstrasse 13 50672 Cologne/Germany T +49 221 20 52-0 F +49 221 20 52-1 Munich Prinzregentenstrasse 48 80538 Munich/Germany T +49 89 540 31-0 F +49 89 540 31-540 Stuttgart Augustenstrasse 1 70178 Stuttgart/Germany T +49 711 22 04 579-0 F +49 711 22 04 579-44 Brussels Rue Froissart 95 1040 Brussels/Belgium T +32 2 646 20-00 F +32 2 646 20-40 Zurich Bahnhofstrasse 3 8001 Zurich/Switzerland T +41 44 200 71-00 F +41 44 200 71-01 www.heuking.de 13.06.2017 DVFA Life Science Conference 2017 12 Thank you very much for your attention!
  • 111. 1 DIGITAL HEALTH TRENDS - WHAT ARE THE OPPORTINITIES FOR VENTURE CAPITAL June 2017 The material set out in this draft document is confidential and may not be discussed with a third party nor passed to any third party except with the authorisation of Creathor Venture. Each person that receives a copy by acceptance thereof represents and agrees that it will not reproduce, distribute or provide it to any other party. Creathor makes no representations or warranties with regard to the documents’ accuracy, completeness, non‐infringement or suitability for a particular purpose.
  • 112. 2Private and Confidential AGENDA Creathor Venture Profile Trends in Digital Health Areas of Interest for Venture Capital
  • 113. 3Private and Confidential AGENDA Creathor Venture Profile Trends in Digital Health Areas of Interest for Venture Capital
  • 115. 5Private and Confidential OUR TEAM WITH PROVEN TRACK RECORD TEAM OVERVIEW PlatformServices Cédric Köhler Team Support (DE) Angela Will-Jamin Finance Manager Adrian Giessler Team Support (DE) Ute Molders Christian Weniger Alex Stöckl Daniel Karsberg Dr. Christian Weiss Marianne Uddman Christian Leikert ManagingPartners InvestmentTeam SupportTeam Thomas Dreiling PR & Com- munications Marketing Swetlana Gross Karlheinz SchmeligDr. Gert Köhler Atanas Mukov Kathrin Leonhard Team Support (CH) Business Intelligence Fabian Degenhardt
  • 116. 6Private and Confidential 30+yearsventurecapitalinvesting 1984 2016 Sold to „Cheetah Mobile“ ­ #3 top app publisher after Facebook and Google 2015 Sold NASH program to „Gilead Sciences“ $1B+ valuation $1B+ valuation $1B+ valuation $1B+ valuation $1B+ valuation $1B+ valuation $1B+ valuation 200+ investments 20 IPOs 1/3 own investment of the managing partners in the fund 7th fund generation
  • 117. 7Private and Confidential INVESTMENT FOCUS Technology HR Finance / Insurance Travel and Mobility Property and Real-Estate NEXTGEN SOFTWARE Internet of Things Sharing Economy Personalized Medicine ArtificialIntelligence (incl. Big Data, Cloud, and autonomus systems) Medtech GROWINGAREA OF TECH- ENABLEDLIFE-SCIENCES Tools Diagnostics
  • 118. 8Private and Confidential INVEStment FOCUS Technology HR Finance / Insurance Travel and Mobility Property and Real-Estate NEXTGEN SOFTWARE Internet of Things Sharing Economy Personalized Medicine ArtificialIntelligence (incl. Big Data, Cloud, and autonomus systems) Medtech GROWINGAREA OF TECH- ENABLEDLIFE-SCIENCES Tools Diagnostics
  • 119. 9Private and Confidential Creathor Venture Profile Trends in Digital Health Areas of Interest for Venture Capital
  • 120. 10Private and Confidential Wearables and biosensing Self Tracking Analytics and Big data Smart Home Care Coordination Telemedicine TRENDS IN Digital Health
  • 121. 11Private and Confidential TRENDS IN Digital Health: Plunging costs of IOT Sensors
  • 122. 12Private and Confidential Source: https://www.genome.gov/sequencingcostsdata/ TRENDS IN Digital Health: Plunging costs OF dNA Sequencing
  • 123. 13Private and Confidential Source: http://www.startuphealth.com/ TRENDS IN Digital Health: VENTURE CAPITAL INVESTMENTS
  • 124. 14Private and Confidential The GERMAN Healthcare System (EUR250BN) 80.2 Million Inhabitants (90% statutatory health insurance, 10% private insurance) 2.000 hospitals 200.000 practitioners 120 health insurance companies 20.000 pharmacies 26.000 nursing homes, residential care homes etc. 1.150 rehab centers/clinics Administration through 200 non-interoperative IT-Systems
  • 125. 15Private and Confidential The GERMAN Healthcare System 80.2 Million Inhabitants (90% statutatory health insurance, 10% private insurance) 2.000 hospitals 200.000 practitioners 120 health insurance companies 20.000 pharmacies 26.000 nursing homes, residential care homes etc. 1.150 rehab centers/clinics
  • 126. 16Private and Confidential Governance of the german healthcare system Government Gesundheitsministerium (Exekutive) Bundestag (Legislative) delegation & decision making Self - administration 2.000 hospitals 200.000 practitioners 120 health insurance companies 20.000 pharmacies 26.000 nursing homes, residential care homes etc. 1.150 rehab centers/clinics
  • 128. 18Private and Confidential History and future of digital health law in germany 2004: GKV-Modernisierungsgesetz … 2015: E-Health Gesetz passed 2018: Roll-Out 1. IT – Infrastructure (gematik) finalized 2. Patient basic data management 3. Emergency Case data 4. E-Medication Plan 5. Telemedicine approaches (e-consultation, e x-ray interpretation) 6. Electronic Health record
  • 129. 19Private and Confidential Creathor Venture Profile Trends in Digital Health Areas of Interest for Venture Capital AGENDA
  • 130. 20 Hypothesis-market pharma & medtech health insurers, single­payer health care systems tech giants (Google, Apple, IBM, Amazon, etc.) try to find innovative solutions for the needs of
  • 131. 21 Hypothesis-needs I. Ability to deliver more personalized patient care II. Engage more fully with physicians and patients III. Advanced analytics to increase pipeline and commercial value
  • 132. 22 Hypothesis-needs Sensors and digital services for tailored, 24/7 treatment E.g. mobile app for managing type 2 diabetes, smartphone­based electrocardiogram, etc. I. Ability to deliver more personalized patient care
  • 133. 23 Hypothesis-needs Omnichannel conversations with physicians and patients Anytime­anywhere virtual care – portals, apps, online patient communities I. Ability to deliver more personalized patient care II. Engage more fully with physicians and patients
  • 134. 24 Hypothesis-needs I. Ability to deliver more personalized patient care II. Engage more fully with physicians and patients III. Advanced analytics to increase pipeline and commercial value
  • 135. 25 III. Advanced analytics to increase pipeline and commercial value Hypothesis-needs In R&D ­ digital discovery and testing of molecules with advanced modeling and simulation techniques “in silico screening” In clinical development speed up recruitment (via social networks) Patient monitoring (Sensors & mobile apps) Electronic data capture & storage In Marketing and Sales ­ advanced analytics to understand prescribing behavior and potential patient profiles, enabling more precise targeting
  • 136. 26Private and Confidential Company Name Short Profile Creathor’s Role Mobile testing Co‐lead Developer of the world’s smartest connected bike system Co‐lead Multi‐modal travel booking platform Investor Meta‐search and booking platform for rental cars Co‐lead Mobile job marketplace Co‐lead Mobile corporate e‐health solution and platform Investor Indoor navigation solution Investor Digital insurance manager Investor International B2B online sales and marketing tool Co‐lead Ai‐enhanced marketplace for expert translations Co‐lead Mobile app (brain training) Co‐lead Market place for local crowd‐sourced service ecosystem Investor Machine‐to‐machine communication for industrial applications Co‐lead Mobile shopping and payment platform Lead Mobile advertising Lead Online referral marketing software & services Lead Video marketing platform Lead Web based sales support system Lead Hotel booking solution Lead Heyjobs Lead investor or CO-Lead investor in majority of investments Active Portfolio - Technology
  • 137. 27Private and Confidential Company Name Short Profile Creathor’s Role Innovative drug delivery platform with a focus on controlled‐release formulations Lead High throughput multiplex protein/DNA analysis for both basic and clinical research Co‐lead Chemical proteomics technology that permits the analysis of small molecule interactions within protein mixtures in a targeted and directed manner Lead Recombinant proteins previously out of reach & scalable viral vectors Co‐lead The Prostatype® Test System – a new gene test for prostate cancer patients Co‐lead Proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks Co‐Lead Dedicated products and services for membrane protein applications that facilitate analysis and drug development Lead Secure, smart and simple healthcare communication for doctors, patients and medical professionals Investor Drug discovery and development company focused on small‐molecule drug discovery with a special emphasis on the target class of nuclear receptors Co‐lead CE marked lacrimal stent for the treatment of Chronic Rhinosinusitis (CRS) and Epiphora Investor Viral vector technologies from gene therapy and vaccination development to customization of cell modelling tools Lead Significant ownership percentage and board positions in majority of investments Active Portfolio - Life Sciences
  • 138. Sample to Insight Next-generation sequencing and big data Jason T. Gammack Vice President; Marketing & Product Management Head of Global Marketing & Strategic Portfolio Management DVFA Conference, June 2017 1
  • 139. Sample to Insight Disclaimer 2 Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law. Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results. GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements. DVFA Conference, June 2017
  • 140. Sample to Insight DVFA Conference, June 2017 SCIENTIFIC BREAKTHROUGHS WE ARE EXPERIENCING A NEW AGE OF Dramatic breakthroughs in molecular biology enable big data creation We are creating more biological data every 6 months than in all of prior history 1) Source: Cisco Systems, GenBank and Alliance Bernstein 3
  • 141. Sample to Insight DVFA Conference, June 2017 4 Data phase Astronomy Twitter YouTube Genomics Acquisition 25 zetta-bytes/year 0.5-15 billion tweets/year 500-900 million hours/year 1 zetta-bases/year Storage 1 EB/year 1-17 PB/year 1-2 EB/year 2-40 EB/year Analysis In situ data reduction Topic and sentiment mining Limited requirements Heterogenous data and analysis Real-time processing Metadata analysis Variant calling, -2 trillion central processing unit (CPU) hours Massive volumes All-pairs genome alignments, - 10,000 trillion CPU hours Distribution Dedicated lines from antennae to server Small units of distribution Major component of modern user’s bandwidth (10MB/s) Many small (10 MB/s) and fewer massive (10 TB/s) data movement Genomics is truly a big (BIG!) data environment The four domains of big data in 2015(1) 1) Source: Stephens ZD, Lee SY, Faghri F, Campbell RH, Zhai C, et al. (2015) Big Data: Astronomical or Genomical?
  • 142. Sample to Insight DVFA Conference, June 2017 5 Rapidly evolving sequencing techniques initiated a new era of genomic insights 1953 1977 Sanger develops 1st DNA sequencing technique 1st personal human genome is sequenced 1st bacterium genome is sequenced 1995 2002 1st mammal genome is sequenced 2009 First NGS tumor genome analysis 1st Illumina human genome is sequenced 2008 1st 454 human genome is sequenced Next-generation DNA sequencing technology is introduced 2007
  • 143. Sample to Insight DVFA Conference, June 2017 6 The growth of DNA sequencing 1) Source: Stephens ZD, Lee SY, Faghri F, Campbell RH, Zhai C, et al. (2015), Big Data: Astronomical or Genomical? The power of genomics is fueled by big data
  • 144. Sample to Insight DVFA Conference, June 2017 7 How can we extract insights from increasingly large and complex data?
  • 145. Sample to Insight 8DVFA Conference, June 2017 How can we share data And find new models of collaboration?
  • 146. Sample to Insight 9DVFA Conference, June 2017 How can we scale interpretation despite skill and time requirements?
  • 147. Sample to Insight 10DVFA Conference, June 2017 How can we use Big Data to make better treatment decisions?
  • 148. Sample to Insight DVFA Conference, June 2017 11 PharmaAcademia Molecular Diagnostics Applied Testing QIAGEN well-positioned across all segments of the NGS market GeneReader NGS System Universal NGS  Single-cell genomics  Gene expression  Targeted resequencing  Whole exome  Whole genome  Clinical research  Translational medicine  Oncology  Hereditary diseases  Infectious diseases Interpretation Nucleic acid collection & extraction Target enrichment Library preparation Next- generation sequencing Data analysis Universal NGS: QIAseq portfolio Universal NGS: CLC / Ingenuity / QCI GeneReader NGS System
  • 149. Sample to Insight 12 QIAGEN Bioinformatics driving innovations from R&D to the clinic Research & Discovery Clinical Development Microbial Pro Suite IPA Genomics Workbench Genomics Server Microbial RNA-Seq Microbial Epigenetics ExploreRNA HVSS IVA Biomedical Workbench HVSS HGMD QCI-Analyze QCI-Interpret Knowledge base curation Services Algorithm development DVFA Conference, June 2017
  • 150. Sample to Insight 13 Delivering faster and better insights across full range of customer needs DVFA Conference, June 2017 Acquisition of OmicSoftEnhancing QIAGEN Bioinformatics portfolio  Leader in enterprise solutions for large-scale omics data management  Curation, standardization and comparative analysis of large-scale NGS and omics datasets  Adds infrastructure solutions for  Own data mining  Data sharing  Adds highly curated data set Highly curated literature Data sharingHighly curated content Own data mining NEW NEW QIAGEN now covers the full range of data interpretation and sharing needs
  • 151. Sample to Insight 14 Actionable insights Expertise and service First complete NGS workflow Flexibility to fit needs Reliable resultsEase of use Unique automation Data interpretation QIAcube® GeneRead QIAcube® GeneReaderTM Bioinformatics portfolio Predictable costs The world’s first complete Sample to Insight NGS solution for actionable results 1 3 4 52 DVFA Conference, June 2017
  • 152. Sample to Insight DVFA Conference, June 2017 15 Setting new standards with QIAGEN Clinical Insight in clinical decision making QCI workflow  Full integration for fast and seamless data analysis  Easy-to-use analysis tool for clinical researchers  Efficient pre-designed data analysis optimized to panel content  Operational scale: workflow and decision-assisted automation  Aligned with regulatory and reimbursement requirements  Integration of HGMD (Human Gene Mutation Database) Identify variants Analyze Review Report QIAGEN Clinical Insight is an integral part of GeneReader NGS workflow
  • 153. Sample to Insight 0 10 20 30 40 50 60 70 80 90 Manual QCI Interpret Hours DVFA Conference, June 2017 16 QIAGEN Clinical Insight: Helping to achieve faster and more accurate insights 75% time reduction InterpretationLiterature curation Case study: the power of QIAGEN Bioinformatics 33% reduction in variants of unknown significance 0 10 20 30 40 50 60 70 80 90 Pathogenic Likely Pathogenic VUS Likely Benign Benign Variants With QIAGENWithout QIAGEN Case study: Cardiology variant classification(1)Case study: QCI interpretation time benefits (1) Data from QCI Interpret with and without QIAGEN curated primary literature. Data is represented as the difference between variant classifications with QIAGEN content minus variant classifications without QIAGEN content.
  • 154. Sample to Insight Screening Diagnosis Prognosis Treatment Monitoring Surveillance DVFA Conference, June 2017 17 Molecular methods support decision making along the patient journey
  • 155. Sample to Insight DVFA Conference, June 2017 18 QCI Interpret: Streamlining interpretation and reporting of NGS data
  • 156. Sample to Insight DVFA Conference, June 2017 19 QCI Interpret: Streamlining interpretation and reporting of NGS data
  • 157. Sample to Insight Solving challenges of complex genomic data Market leader in analysis, interpretation and content Portfolio with strong commercial traction 20 Summary DVFA Conference, June 2017
  • 158. Clemens Suter-Crazzolara, PhD. May 2017 The Health Revolution – Better Outcomes with Smart Data
  • 159. 2© 2017 SAP SE or an SAP affiliate company. All rights reserved. Legal Disclaimer The information in this document is confidential and proprietary to SAP and may not be disclosed without the permission of SAP. This document is not subject to your license agreement or any other service or subscription agreement with SAP. SAP has no obligation to pursue any course of business outlined in this document or any related presentation, or to develop or release any functionality mentioned therein. This document, or any related presentation and SAP’s strategy and possible future developments, products and or platforms directions and functionality are all subject to change and may be changed by SAP at any time for any reason without notice. The information on this document is not a commitment, promise or legal obligation to deliver any material, code or functionality. This document is provided without a warranty of any kind, either express or implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. This document is for informational purposes and may not be incorporated into a contract. SAP assumes no responsibility for errors or omissions in this document, except if such damages were caused by SAP intentionally or grossly negligent. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, and they should not be relied upon in making purchasing decisions.
  • 160. 3© 2017 SAP SE or an SAP affiliate company. All rights reserved. Global Trends Impacting Patients and the Industry at Large Escalating Costs Increasing Demand ‘Sleeping Giant’: Patients as Consumers
  • 161. 4© 2017 SAP SE or an SAP affiliate company. All rights reserved. Value-Based Care and Patient Outcomes Response to Market Forces Drives Transformational Change Escalating Costs Increasing Demand Patients as Consumers Legislation / Payment Reform MACRA APM MIPS MACRA = Medicare Access and CHIP Reauthorization Act APM = Advanced Alternative Payment Models MIPS = Merit-based Incentive Payment System Population Health, Disease Management and Precision Medicine Patient Engagement
  • 162. 5© 2017 SAP SE or an SAP affiliate company. All rights reserved. The Opportunity: Combining Cross Ecosystem Data in Innovative New Ways to Reveal Breakthrough Findings Patient timeline PubMed Biomedical Article Database Clinical Trials Currently more than 30,000 recruiting on ClinicalTrials.gov Cancer Patient Records at the National Center for Tumor (NCT) Diseases in Heidelberg Clinical information management systems Often more than 50 GB Human Proteome data points (2.4 GB) per sample; 7.6 TB raw proteome data on ProteomicsDB.org Prescription Data records from 10,000 doctors and 10 million patients (100 GB) Human Genome and Biological Data from a single genome; >15 PB in databases of leading institutes Medical Imaging Data 1 second scan of a single organ Gain Longitude Views of Patient Healthcare History Gain Comprehensive Views of Cross-Population Health and Industry Insights 160M 1.5B 50GB 160K >25M 10GB 800MB 30K Diagnosis Tumor Stage Pathology Report Tissue Sample Genomic Markers Radiotherapy
  • 163. 6© 2017 SAP SE or an SAP affiliate company. All rights reserved. Framework for Live Business from SAP
  • 164. 7© 2017 SAP SE or an SAP affiliate company. All rights reserved. S4 PA S4 ERP Patient Relationship Management SAP Expertly Applies Technology within Healthcare Business Contexts to Power Innovation Research and Clinical Delivery How do I assemble and manage my care team based on the needs of my patient? How do I design and run my supply chain based on the needs of my patients? S4 ERP Ariba Fieldglass SucessFactors S4 PM SAP Health Leonardo Co-Innovation Patient Revenue Optimization • How do I maximize my revenue and collections from patient (billing) • How to acquire new patients and retain existing ones (marketing)? Research & Clinical Delivery How do I enable my clinicians to deliver evidence-based care Supply Chain/ Ops Workforce Engagement
  • 165. 8© 2017 SAP SE or an SAP affiliate company. All rights reserved. Specialized Hospitals Rehabilitation Community Practice Pharma Research Payer Medical Devices LabsProviders SAP Health Enables Actionable Insights by Leveraging the Healthcare Ecosystem Patient Connected Integrate evolving data sets across the healthcare continuum Real-time Provide up-to-the-moment insights for improved decision making and greater patient and population health insights Actionable Advanced analytics and queries to spot trends, run scenarios, set new standards for treatment and delivery
  • 166. 9© 2017 SAP SE or an SAP affiliate company. All rights reserved. SAP Health Drives Innovation as the Catalyst for Healthcare Transformation SAP Applications • Patient Engagement • Patient Management • Clinical Research • Clinical Quality . Partner Applications Facilitates Healthcare Network collaboration through integrated insights and application services that support coordinated patient-centric, health and wellness scenarios SAP Federated Data and Analytics Connecting data silos, providing real time insights, and supported by SAP HANA in- memory computing for improved decision- making, hypothesis-building and testing Accelerated Innovation with broad application portfolio, connected medical devices, automation and machine learning Integrated User Interface SAP Health Platform SAP HANA Platform